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ABSTRACT
CO-SENSITIZATION OF DOPAMINE AND SEROTONIN RECEPTORS OCCURS
IN THE ABSENCE OF A CHANGE IN THE DOPAMINE D, RECEPTOR
COMPLEX AFTER A NEONATAL 6-OHDA LESION
by
Li Gong
To test whether SKF 38393 could ontogenetically
sensitize dopamine (DA) D, receptors and whether this
sensitization would be associated with biochemical changes,
intact and neonatal 6-hydroxydopamine (6-OHDA)-lesioned rats
(200 pq i.c.v.) were treated daily from birth with SKF 38393
(3.0 mg/kg i.p. x 28 days) or its vehicle. In DA D,
neonatally sensitized 6-OHDA rats, enhanced locomotor
responses were observed with the first SKF 38393 challenge
dose (3.0 mg/kg i.p.) at 6 weeks. This response increased
further with weekly SKF 38393 treatments. Enhanced
stereotyped behaviors were seen in both lesioned and
sensitized rats at 8 weeks. There was no change in the
percentage of high affinity D, sites in these groups of
rats. Striatal mRNA levels for D, receptors were reduced in
the lesioned rats, but restored to control level after
treatments with SKF 38393 in adulthood. Basal, DA-, NaFand forskolin-stimulated adenylate cyclase activities were
similar among treatment groups. Striatal DA content was
reduced (>99%), whereas serotonin (5-HT) content was
elevated (>50%) in the 6-OHDA groups. To study possible
interaction between DA and 5-HT systems, the effects of a
series of 5-HT agents on the induction of oral activity were
determined. The 5-HTlc receptor agonist, mchlorophenylpiperazine (m-CPP), produced a marked increase
in oral activity in 6-OHDA-lesioned rats. The respective 5HT,A and 5-HT,B agonists, 8-OH-DPAT and CGS-12066B did not
increase oral activity. The m-CPP-induced oral response in
the lesioned rats was attenuated by mianserin, a 5-HT,c
antagonist, but not by ketanserin or MDL-72222, 5-HT2 and 5HTj antagonists, respectively. Although the supersensitized
oral response of lesioned rats to m-CPP was not attenuated
by SCH 23390, the enhanced response of SKF 38393 was
attenuated by mianserin. Additionally, mRNA levels for 5HT1C receptor were not altered in both intact and lesioned
rats. These findings demonstrate that ontogenetic
treatments of neonatal 6-OHDA-lesioned rats with a D,
agonist produce partial sensitization of DA D, receptors in
adulthood without altered biochemical markers, and that this
neonatal lesion is associated with both supersensitized DA
D, and 5-HTlc receptors. Moreover, induction of oral
activity by DA agonists is mediated via a serotonergic
system.
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Chapter 1
Introduction

Anatomical Review of Dopamine system
Dopamine (DA), a veritable newcomer to the field of
monoamine transmitters in mammalian central nervous system
(CNS), belongs to a class of compounds termed catecholamines
(Montagu, 1957).

Until the mid-1950s DA was simply

considered to represent an intermediate precursor in the
biosynthesis of norepinephrine and epinephrine.

Because the

concentration of DA is almost equal to those of
norepinephrine in the brain, and because the regional
distribution of these two catecholamines is markedly
different, it was proposed that the biological role for DA
in CNS is independent of its function as a precursor in
norepinephrine synthesis (Carlsson et al., 1958? 1959).
With the development of histochemical and immunocytochemical
methods for visualizing catecholamines in brain tissue
sections (Dahlstrom and Fuxe, 1964? Fuxe et al., 1978), it
is now convenient to localize dopaminergic pathways under
several major categories as follows:
l. Nigrostriatal DA system,

A group of cell bodies,

designated the A9 group, are located primarily in
the substantia nigra pars compacta.

These neurons

project mainly into neostriatum (principally the
caudate and putamen), globus pallidus and
1

subthalamic nucleus.
2. Hesollmbic DA system.

One group of DA-containing

neurons, known as the A10 group, originates in the
ventral tegmental area and terminates in the
nucleus accumbens, olfactory tubercle and nucleus
interstitialis stria terminalis.
3. Mesocortical DA system.

Neuronal cell bodies are

also located in the ventral tegmental area (A10
group), but their projections end in the septum,
prefrental cortex, cingulate, hippocampus and
amygdala.
4. Mesothalamic DA system. Another group of cell
bodies originates in the ventral tegmental area (A10
group) and terminates in the medial and lateral
habenula.
5. Tuberoinfundibular and tuberohypophyseal DA system.
A system consisting of both short and intermediatelength neurons, designated the A12 group, arises
from the arcuate and periarcuate nucleus and the
ventral periventricular hypothalamic nucleus, and
terminates in the median eminence, infundibular
stalk, intermediate and neural lobes of the
pituitary.

Ontogeny of Dopamine System

Neuron production in the rat is largely prenatal

(Brasel et al., 1970).

The features of the postnatal

developmental process are mainly related to events involving
neuronal growth, axonal outgrowth and the synaptic
formation.

The development of dopaminergic fiber systems in

rats takes place in the first few postnatal weeks.

Several

striatal components including DA-containing nerve endings,
the neurotransmitter DA and DA receptors show transformed
patterns during development.
At birth, dopaminergic fibers can be visualized in
distinct patches' revealed by histofluorescence and
immunocytochemistry (Moon Edley and Herkenham, 1984; Voorn
et al., 1988).

Soon after birth, denser appearance of DA

terminals in a *matrix' pattern in the striatum can be
discerned (Gerfen et al., 1987).

By 3-4 weeks after birth,

the striatal pattern of DA fiber innervation continues to
mature and appears to reach an adult-like alignment (Moon
Edley and Herkenham, 1984; Voorn et al., 1988).
similarly, DA content in the developing brain exhibits
the same picture (Loizou and Salt, 1970).

At the first day

after birth, the striatum contains only about 12% of the
adult level of DA (Giorgi et al., 1987).

The striatal DA

level increases slowly thereafter, reaching adult levels 7-8
weeks after birth and remaining constant throughout
adulthood (Breese and Traylor, 1972; Giorgi et at., 1987;
Broaddus and Bennett, 1990).
Ontogenetic studies with neonatal rats demonstrated

that a first-week postnatal striatum lacks spontaneous
neuronal activity (Cheronis et al., 1979; Napier et al.,
1985).

Striatal neuronal activity can be recorded from 17

day old pups.

As the variety of striatal cell firing

patterns increased with age, 28 day old rats have been
observed to have similar patterns often seen in adult
striatum (Napier et al., 1985).
The above mentioned findings indicate that
developmental changes occur in nigrostriatal dopaminergic
projections and their connections especially during the
first 8 weeks after birth.

proposed Functions of Dopamine System

Based on anatomical, biochemical, behavioral and
pharmacological characteristics, there is compelling
evidence that DA serves as both a neurotransmitter and a
modulator in the brain.

The physiological role of the

central dopaminergic system has been proposed as follows:
1. Behavioral modulation.

A variety of behaviors are

found to be regulated by the dopaminergic system.
In general, the nigrostriatal pathway may largely
modulate motor behavior (Ungerstedt and Arbuthnott,
1970; Ungerstedt, 1971a,b), as evidenced by
characteristic motor disorder associated with its
degeneration in Parkinson's disease (Hornykiewicz,
1966).

Numerous studies have suggested that

mesolimbic and mesocortical pathways regulate not
only motor function, but mainly emotional and reward
behavior, as well as cortical and subcortical
functions, i.e. stereotyped behaviors (Creese and
Iversen, 1973), self-stimulation behavior (Phillips
and Fibiger, 1973), stimulus control behavior (Ho
and Huang, 1975) and locomotion (Pijnenburg et al.,
1976).

Dysfunction of mesolimbic dopaminergic

pathway has been hypothesized to underlie the
etiology of schizophrenia and depression (Stevens,
1973).
2. Neuroendocrine function.

The tuberinfundibular DA

system regulates secretion of prolactin and
gonadotropin releasing hormone, and inhibits release
of somatostatin and thyrotropin releasing hormone.

Dopamine Receptors

Ample evidence has been provided that there are
multiple receptors for DA in the CNS, on the basis of
pharmacological, biochemical, anatomical and physiological
features (Kebabian and Caine, 1979; Creese and Leff, 19S2;
Creese et al., 1983; Stoof and Kebabian, 1984).
Classically, upon agonist stimulation, DA D, receptors are
associated with activation of adenylate cyclase (AC)
(Kebabian and Caine, 1979; Seeman, 1980).

DA Dj receptors,

on the other hand, are either unlinked to stimulation of AC,

or have an inhibitory effect on the enzyme (Memo et al.,
1986; Onali et al., 1984; 1985).

characterization and Localization of Dopamine p. Receptors
Pharmacological studies, performed with radioligand
binding to discriminate between these two receptor
categories, have aided substantially in characterizing DA
receptor populations.

Dt receptors have been characterized

by using (JH]-cis**(Z)-flupenthixol (Hyttel, 1978; Murrin,
1983) and [3H]-cis-(Z)-piflutixol (Hyttel, 1981).

However,

both radioligands produce similar affinities for D( and Dj
receptors and cause a high degree of nonspecific binding.
SCH 23390 [R-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl5-phenyl-lH-3-benzazepine-7-ol] was later introduced as the
first highly selective D, receptor antagonist and designated
as the most suitable ligand for D, receptors (Hyttel, 1983;
Iorio et al., 1983; Billard et al., 1984; Schulz et al.,
1984; Andersen et al., 1985).

In vitro, SCH 23390 potently

blocks DA-stimulated adenylate cyclase (Iorio et al., 1983)
and selectively displaces [3H]-piflutixol binding from
striatal slices (Hyttel, 1983).

However, in the [JH]-

spiperone binding assay (a ligand for D2 receptor), SCH
23390 displays a relatively low affinity at the micromolar
range and is about 460 times weaker than other neuroleptics
such as haloperidol.

in vivo, this compound is a potent and

selective antagonist of the D, receptor, with little

affinity toward D2 receptors in the CNS (Andersen and
Groenvald, 1986; Andersen and Nielsen* 1986).
Regional distribution and density of DA Dt receptors in
rat brain have been described by using autoradiographic
studies with [3H] SCH23390.

The highest density of D,

receptors was found in the caudate-putamen, nucleus
accumbens, olfactory tubercle and the substantia nigra par
compacta or pars reticulata (Dawson et al., 1986; Savasta et
al., 1986).

High densities was also observed in amygdala,

nucleus interstitialis stria terminalis, entopeduncular
nucleus and island of Calleja.

Moderate to low numbers of

Dj sites was found in cerebral cortex, several thalamic,
hypothalamic and hippocampal areas, the habenula, the
ventral tegmental area, the cingulate and the cerebellum.
The topographical distribution of D, receptors in the
striatum was much greater in the ventrolateral and medial
margin subregion than in the ventromedial and dorsolateral
sectors, and a rostrocaudal decrease in the densities of D,
receptors was also noticed (Savasta et al., 1986).
The regional localization of mRNA for Dt receptors has
been determined by northern blot and by in situ
hybridization histochemistry.

In general, the areas of

highest expression of D, receptors are the caudate-putamen,
nucleus accumbens and olfactory tubercle.

D, receptor mRNA

is also observed in the cerebral cortex, limbic system,
hypothalamus and thalamus (Fremeau et al., 1991; Sibley and

8
Monsma, 1992).

Signal Transduction Systems of Dopamine D, Receptors

Striatal DA D, receptors have been shown to mediate the
DA-stimulated increase of adenylate cyclase (AC) activity
(Kebabian and Caine, 1979).

In membrane preparations, the

stimulation of AC activity can also be elicited by GTP and
forskolin, which specifically act on stimulatory guanine
nucleotide regulatory protein (N.) or catalytic subunit of
the enzyme, respectively, rather than the receptor site
(Rodbell, 1980; Seamon et al., 1981).

DA, GTP and forskolin

thus have been widely used as biochemical markers in
adenylate cyclase assays to determine the functional
integrity of each subunit in DA Dt receptor complex system,
and to investigate Dt receptor/effector mechanisms.
There are also growing lines of evidence that
stimulation of DA receptors leads to changes in
phosphoinositide metabolism.

An early study by Hokin (1970)

showed variable effects of DA on incorporation of nP into
phosphatidate and phosphatidylinositol in slices of the
guinea pig brain.

Later, both stimulatory and inhibitory

effects of DA on phosphoinositide labeling were found
(Abdel-Latif et al., 1974; Odarjuk et al., 1986).

Undie and

Friedman (1990) demonstrated that the stimulation of DA D(
receptors enhances inositol phosphate formation in rat
brain.

By injecting mRNA from rat striatum into oocytes of

9
Xenopus laevis, Mahan et al. (1990) also showed the
expression of striatal D, receptors coupled to inositol
phosphate production.

Dynamics of Dopamine D, Receptors

The binding of antagonists to DA D, receptors show mass
action characteristics, whereas agonist binding displays two
separate states of high and low affinity (Hamblin et al.,
1984; Leff et al., 1985).

This heterogeneity was

demonstrated by shallow two-component curves of agonist
competition for radiolabeled antagonist binding.

In the

presence of guanine nucleotides, the high affinity agonistreceptor complex is converted to low affinity agonist
binding states of the receptors (Hamblin et al., 1984; Leff
et al., 1985; Hess et al., 1986).

These studies have

proposed a generalized ternary complex model to explain
these phenomena, which has been modified from the original
models of Boeynaems and Dumont (1975) and Jacobs and
Cuatrecasas (1976), and proposed for several other
monoaminergic receptors (Limbird, 1981).

Qntoaenv of Dopamine D, Receptors

Dopaminergic innervation of the striatum plays an
important role in regulating the development of neurons
intrinsic to the striatum (Rosengarten and Friedhoff, 1979).
There is increasing evidence that the ontogeny of DA

receptors and their mediated responses are dependent upon
the maturation of their corresponding presynaptic nerve
terminals.

DA Dt receptors are at low levels at birth (9%

of the adult value) and increase in number thereafter
(Giorgi et al., 1987; Zeng et al., 1988), attaining a peak
value at postnatal day 35 (Giorgi et al., 1987).

There were

no alterations in affinity (Kd) of [JH]piflutixol and[3H]SCH
23390 for D, receptors during development (Zeng et al.,
1988; Gelbard et al., 1989; Broaddus and Bennett, 1990).
Giorgi et al. (1987) showed that maximum DA-stimulated
adenylate cyclase (AC) activity in striatum has a
developmental profile similar to DA Dt receptors, suggesting
that the postnatal increase in AC activity is attributable
to the increase in stimulatory receptor density.

The

ontogeny of D, receptors parallels those seen with several
other markers associated with presynaptic dopaminergic
terminals in striatum, including DA content, DA uptake
(Coyle and Campochiaro, 1976), and tyrosine hydroxylase
activity (Coyle and Axelrod, 1972).

Molecular Biology of Dopamine Receptors

With the molecular characterization of DA receptors
being facilitated by the cloning of cDNAs and/or genes, two
subtypes of DA D, receptors and four subtypes of D2 receptors
have already been identified.

The D, receptor of human and

rats in CNS has been cloned, expressed and characterized

11
(Zhou et al., 1990; Dearry et al., 1990), while its subtype,
termed Djr has recently been identified and cloned as well.
The Dj receptor bears resemblance to the cloned D, receptor.
But pharmacologically, the D5 receptor has a 10-fold higher
affinity for the endogenous agonist, DA (Sunahara et al.,
1991.).
Two forms of the DA D* receptor, D2 short and D2 long,
were identified by gene cloning and found to be derived from
alternative splicing of a common gene (Dal Toso et al.,
1989; Giros et al., 1989).

A third subtype of the D2

receptor, termed Dj receptor and characterized by its
different anatomical distribution and pharmacological
profile, was isolated by the screening of rat brain cDNA and
genomic libraries (Sokoloff et al., 1990; Bouthenet et al.,
1991).

The fourth subtype of the D2 receptor, the D4

receptor, has been recently cloned.

Its pharmacological

profile is similar to that of the D2 and Dj receptors.

The

affinity of the D4 receptor for the atypical antipsychotic
drug, clozapine, however, is an order of magnitude higher
than for D2 and D3 receptors (Van Tol et al., 1991).
A better understanding of which DA receptor subtype
mediates particular physiological effects would greatly
facilitate the development of more specific dopaminergic
agents and provide insight into the mechanisms of disorders
thought to be related to the malfunctioning of the DA
system.
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Innervation of Serotonin Flbera to the Striatum
The existence of serotonin (5-HT) innervation in
mammalian neostriatum was first shown by regional
biochemical examination of this monoamine, and by activity
of its biosynthetic enzyme, tryptophan hydroxylase in the
dog and cat brain (Bogdanski et al., 1957; Peters et al.,
I960).

Fluorescent histochemical and autoradiographic

investigations further provided evidence of this 5-HT
innervation in rat striatum (Arluison and Delamanche, 1980;
van der Kooy and Hattori, 1980; Parent et al., 1981).

The

distributional characteristic of the 5-HT innervation in
adult rat striatum demonstrated a marked heterogeneous
pattern (Ternaux et al., 1977; Steinbusch, 1981).

The

neostrlatal 5-HT fiber network has a higher density in
ventral vs. dorsal parts, and a caudo-rostral decreasing
density gradient was also found (Steinbusch, 1981;
Soghomonian et al., 1987).

This topographic distribution

was consistant with regional biochemical measurements,
demonstrating that higher levels of intrastriatal 5-HT
content or [JH]5-HT uptake is noted in the ventral vs.
dorsal, and the caudal vs. rostral parts of adult striatum
(Beal and Martin, 1985; Widraann and Sperk, 1986).

Although

the heterogeneous distribution of the striatal 5-HT
innervation remains of obscure significance, a complementary
striatal pattern of the distribution of DA and 5-HT
terminals has been found in the rostral to caudal, and
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dorsal to ventral axes (Tassin et al., 1976; Doucet et al.,
1986).

On the other hand, the striatal 5-HT innervation

density is ouch less than that of DA fiber innervation
(Doucet et al., 1986).

A critical balance between

dopaminergic and serotonergic neurons has been postulated to
underlie normal motor activity, based on biochemical and
lesion studies (Sourkes and Poirier, 1968).
Lidov and Molliver (1982) reported that 5-HT
innervation in neonatal rats does not show a mosaic pattern
of patches and matrix organization, and the major
development of this innervation takes place 12-15 days after
birth.

This is in contrast with the DA innervation in

striatum, where at the earlier postnatal stage, the
prominence of DA islands is found (Olson et al., 1972; Voorn
et al., 1988).

Serotonin Receptors in Striatum
Based on biochemical, pharmacological and behavioral
studies, at least seven distinct subtypes of 5-HT receptors
are currently identified in mammalian central nervous system
(Frazer et al., 1990; Peroutka et al., 1990; Glennon and
Dukat, 1991).

Many subtypes of this receptor family have

now been cloned (Julius et al,, 1988; Pritchett et al.,
1988; Albert et al., 1990; Hamblin and Metcakf, 1991; Maricq
et al., 1991; Voight et al., 1991; Weinshank et al., 1992).
5-HT, group can be divided into four classes (labeled 5-HT,A
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through 5-HT1D), while the three other groups are designated
5-HT2, 5-HTj and 5-HT4.
There is a relative lack of 5-HT,A receptor in rat
striatum (Marcinkiewicz et al., 1984; Verge et al., 1986),
recently confirmed by immunocytochemistry and in situ
hybridization of the mRNA (El Mestikawy et al., 1991; Riad
et al., 1991; Chalmers and Hatson, 1991; Miquel et al.,
1991).

Autoradiographic studies show that the 5-HT10

receptor subtype occurs in rat striatum (Pazos and Palacios,
1985).

Destruction of 5-HT innervation to striatum with the

5-HT neurotoxin, 5,7-dihydroxytryptamine (5,7-DHT), results
in increased striatal [m I]cyanopindolol binding, suggesting
postsynaptic 5-HTtB sites in the striatum (Offord et al.,
1988; Palacios and Dietl, 1988).

5-HTlD receptors have been

identified in the brain of rat, guinea pig and other species
(Herrick-Davis and Titeler, 1988; Herrick-Davis et al.,
1989; Waeber et al., 1990).

Quinalinic acid lesion of

striatal neuronal bodies induces a decrease of 5-HTID
receptors in substantia nigra, globus pallidus and striatum,
suggesting that their possible location either on cell
bodies, dendrites or terminals of interneurons (tfaeber et
al., 1990).

in the striatum, 5-HTj receptors have an

intermediate density, as determined by autoradiographic
studies (Pazos et al., 1985a; Palacios and Dietl, 1988).
Lesion of 5-HT system by 5,7-DHT did not reduce the number
of 5-HTj sites in rats (Fischette et al., 1987).

Therefore,

IS

it is likely that the 5-HTj receptors are located on non-5HT neurons.
The 5-HTlc receptors were initially found to be present
at high density in the choroid plexus (Pazos et al., 1985b).
Since the pharmacological characteristics of this receptor
subtype are similar to those of 5-HT2 receptors, it was
suggested that they might be in the same receptor family
(Hoyer et al., 1988).

Autoradiographic studies demonstrated

that 5-HTic receptors are present at low levels in many
areas of the brain.

But studies of the distribution of the

mRNA encoding for 5-HT]C receptors confirmed and also
extended these results (Hoffman and Mezey 1989; Molineaux et
al., 1989; Mengod et al., 1990), indicating that mRNA and
binding sites for this particular 5-HT receptor subtype are
heterogeneously distributed in the rodent brain including
striatum.

It was proposed that 5-HT,c receptors could be

involved in the regulation of many different brain functions
(Julius et al., 1988; Hoffman and Mezey, 1989; Mengod et
al., 1990).

The 5-HT,c receptors have been studied more

extensively in choroid plexus than in any other brain area.
They appear to be located on epithelial cells where they
regulate the production and composition of cerebrospinal
fluid (Pazos and Palacios, 1985).

Since lesion of the

dopaminergic system did not alter 5-HTlc binding in this
area, it was suggested that this receptor subtype is not
located on dopaminergic neurons (Palacios and Dietl, 1988).
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Supersensitization of 5-HTlc receptors produced by 5,7-DHT
lesion, suggested that these receptors are present on nonserotonergic neurons (Conn et al., 1987),

The postnatal

development of 5-HTIC receptors has been studied in rat
brain choroid plexus, although little is known about their
ontogeny in other brain regions.

The number of binding

sites increases markedly between day 3 and 20 after birth
(Zilles et al., 1986), and these receptors appear to develop
earlier than other 5-HT, receptor subtypes.

Accompanying a

2-fold increase in 5-KTlc binding sites in rat brain between
day 17 and 27 after birth, there is a 5-fold increase in
corresponding mRNA levels (Roth et al., 1991).

The

mechanisms responsible for regulating 5-HT,c receptors by
exogenous or endogenous compounds are not currently clear
(Roth et al., 1990).
5-HTj receptors have been found mainly in brain
postrema and other brain areas including cortex, amygdala
and hippocampus, rather than striatum (Kilpatrick et al.,
1987; Barnes et al., 1990).

When compared to other

serotonergic receptors, 5-HTj receptors have a particularly
low density in the brain.

5-HT4 receptors might belong to

another functionally important 5-HT receptor family in the
CNS.

So far, the recognition sites for these receptors have

not been identified because they have been hampered by the
absence of a high affinity radioligand (Bockaert et al.,
1992).
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6-Hvdroxvdopamine and Dopamine Receptor SupersensItigation
6-hydroxydopamine (6-OHDA), a neurotoxin, selectively
destroys brain catecholamine-containing neurons and their
terminals (Breese and Traylor, 1970; Uretsky and Iversen,
1970; Kostrzewa and Jacobowitz, 1974).

6-OHDA provides a

pharmacological means to explore central dopaminergic
function in adult fUngerstedt and Arbuthnott, 1970; Kelly et
al., 1975; Creese et al., 1977) and developing rats (Breese
et al., 1984; 1985a; 1985b).

In many brain regions, the

reduction or depletion of a dopaminergic afferent input has
been shown to result in a functional postsynaptic receptor
supersensitivity.

Lesions of nigrostriatal pathway in adult

rats produces a motor dysfunction (Breese and Traylor, 1970;
Ungerstedt, 1971c; Zigraond and Strieker, 1973) and
behavioral supersensitivity (Ungerstedt, 1971a,b), which is
accompanied by an increase in the density of DA D3 receptors
in the denervated striatum (Creese et al., 1977; Staunton et
al., 1981).
Although neonatal lesioned rats possess the capacity to
develop apparently normal motor and ingestive behaviors in
the virtual absence of the emerging DA system (Erinoff et
al., 1979; Pearson et al., 1980; Bruno et al., 1986), the
enhanced behavioral responsiveness towards DA D, and D2
agonists and antagonists has also been well documented after
lesion with the toxin (Breese et al., 1984; 1985; 1987;
Duncan et al., 1987).

In a series of studies, Breese and

co-workers (1985) demonstrated that the sensitivity of
neonatal 6-OHDA lesioned rats is often enhanced, with the
animals becoming particularly sensitive to DA D, agonists.
This enhanced behavioral responsiveness was not accompanied
by a change in density (B^) and affinity for either D, or D2
receptors in the striatum (Breese et al., 1987; Luthman et
al., 1990), suggesting that the enhanced response to DA
agonists in neonatal 6-OHDA-lesioned rats could be
reflecting a change in the sensitivity of secondary and
tertiary messenger systems linked to the DA recognition
sites; or an alteration in

non-doparainergic neural

mechanisms which influence the response to DA receptor
stimulation.
Furthermore, results from the same laboratory showed
that repeated treatment of neonatal 6-OHDA-lesioned animals
with SKF 38393, a specific D, receptor agonist (Setler et
al., 1978), led

to a progressive increase in locomotor

activity and several other behaviors in adulthood, a
phenomenon referred to as 'priming' (Breese et al., 1985b;
Criswell et al., 1989).

These actions of SKF 38393 were

blocked by SCH 23390, a specific D( antagonist (Breese et
al., 1985b; Criswell et al., 1989, 1990).

Therefore,

priming of Dt receptor responsiveness in neonatal 6-OHDAlesioned rats represents a model of a long-term alteration
in neural function related to repeated activation of a
receptor system.

Recently, Simson et al. (1992) found that behavioral
supersensitivity in neonatally lesioned rats was not related
to the alteration in the activation of adenylate cyclase,
because no enhancement of cAMP production was observed with
activation of DA D, receptors in lesioned animals.

These

investigators, however, suggested that differences of
regionally enhanced electrophysiological sensitivity of
striatal neurons to Dt agonists and regional distribution
pattern of tyrosine hydroxylase-like immunoreactivity and cfos-like immunohistochemical expression within the striatum
of neonatal lesioned rats, might contribute to the unique
behavioral pattern seen in lesioned rats when they are
challenged with DA D, agonists in adulthood (Johnson et al.,
1992; Simson et al., 1992).

6-Hvdroxvdopamlne and Serotonin System
Another feature of the 6-OHDA lesion in neonatal rats
is a substantial increase in the adult striatal levels of 5hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5HIAA) (Breese et al., 1984; Stachowiak et al., 1984).

This

lesion-induced elevation in 5-HT content is associated with
a corresponding increase in [3H]5-HT uptake (Stachowiak et
al.,1984) and with a proliferation of 5-HT containing fibers
in the rostral portion of striatum (Berger et al., 1985;
Snyder et al., 1986).

The same 6-OHDA denervation of

striatum associated with 5-HT hyperinnervation has also been
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observed in adult lesioned rats and thus it is proposed as
heterotypic terminal outgrowth, in the sense that it
involves excessive growth of a neuronal system different
from that which was lesioned (Zhou et al., 1991).
Autoradiographic study by Radja et al, (1993) demonstrated
that 5-HT1B, 5-HTIoeoAB (including 5-HTlc and 5-HT1D), 5-HT2
receptor subtypes were upregulated in adult rat brain after
a neonatal 6-OHDA lesion to striatum that is associated with
5-HT hyperinnervation in that brain region.

This

upregulation of several 5-HT receptor subtypes was likely to
represent increases in receptor number (B^) rather than the
affinity of the receptors (Kd) (Radja et al., 1993).
Little is known about the functional implications of
such striatal 5-HT hyperinnervation and its corresponding 5HT receptor subtype upregulation in lesioned animals.

In

other studies on neonatal 6-OHDA-lesioned rats it was
reported that the sprouted 5-HT fibers did not seem to have
an inhibitory control on endogenous 5-HT- and acetylcholinecontaining neurons (Jackson et al., 1988).

Towle et al.

(1989) found that 5-HT hyperinnervation was not responsible
for supersensitized locomotor and stereotyped responses to
either a DA or 5-HT agonist in neonatally lesioned rats,
although their emphasis was focused on 5-HT2 receptors.

Dopamine System and^Animal_Bohavloral_Models
Denervation supersensitivity models have been widely

used to study central dopaminergic function, to elucidate
mechanisms of action of DA related agents, and to develop
models of neurological and psychiatric diseases.

As

measured by a variety of enhanced behavioral changes, the
mechanism responsible for this phenomenon of denervation is
supposedly associated with either receptor up-regulation

or

functional changes in second messenger systems with regard
to these receptors.

The best studied animal models are as

follows.
1. Rotational model.

This was first described by Ungerstedt

(1971a), and was produced by injection of 6-OHDA into one
substantia nigra of the rat.

The resultant unilateral

lesion of the nigrostriatal pathway leads to a permanent
depletion of DA in the ipsilateral striatum.

Behavioral

supersensitivity (i.e. contralateral circling) is seen when
the rat is challenged with a DA agonist.

This increased

sensitivity to agonist administration has been correlated
with an increase in striatal DA D2 receptor density
ipsilateral to the lesion (Creese et al., 1977; Hishra et
al., 1980; Heikkila et al., 1981).
2. Stereotypy model.

Tarsy and Baldessarini (1974)

demonstrated that apomorphine-induced stereotyped behavior
was increased in rats after prolonged pretreatment with the
DA synthesis inhibitor, o-methyl-p-tyrosine.

This was

comparable to the effect after chronic administration of
antipsychotic drugs, suggesting that this behavioral
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stereotypy is probably specifically related to compensatory
supersensitivity of OA receptors.

This stereotypy includes

sniffing, rearing, licking, gnawing, chewing and locomotion
behaviors.
3. oral movement model.

Rats chronically treated with

neuroleptics show an increased incidence of purposeless or
vacuous chewing movements, when challenged by DA receptor
agonists (Clow et al., 1979; Klawans et al., 1972;
Waddington et al., 1980).

This oral activity is similar to

the oral-bucial-masticatory movements classically described
in patients with tardive dyskinesia.

The phenomenology of

this oral activity in rats is defined as 'vacuous (or
abortive or spontaneous) chewing, whereby what appear to be
robust chewing sequences are manifested, but are not
directed onto any evident physical material' (Waddington,
1990).

In neonatal 6-OHDA-lesioned rats, the effects of a

D, agonist or D2 antagonist on oral responses are greatly
potentiated, even though the

and Kd for striatal Dt and

Dj receptor binding do not accompany the marked reduction in
DA content (Kostrzewa and Hamdi, 1991).

This indicates that

the enhanced oral movements in these neonatally lesioned
rats are due to supersensitized DA receptors.
4.Catalepsy model.

It is one of the classic rodent models

to induce a state of transient immobility in testing DA
antagonist activity, which is characterized by placing the
forepaw of the rat on a testing bar or on an inclined wire

mesh screen and measuring the cataleptic time on the bar or
the screen (Costall and olley, 1971, Kostrzewa and Kastin,
1993).

This effect is mediated by blockade of striatal DA

receptors (Costall and Olley, 1971; Koffer et al., 1978;
Heller et al., 1985, Kostrzewa and Kastin, 1993).

Brain Dopamine System and Clinical Diseases
Many clinical diseases are known to be specifically
related to malfunctioning of DA systems.
Parkinson's disease is a progressive neurodegenerative
disorder of the basal ganglia.

Although characterized

pathologically by loss of pigmented neurons in the
substantia nigra, the basic biochemistry of the disease was
not known until the 1960s.

It was found that there is a

substantial loss of DA in the striatum (Hornykiewicz, 1966).
It is clear now that the most striking degenerative loss of
DA neurons occurs in the nigrostiatal system.

Studies have

also been carried out on the relationship between the
sensitivity of postsynaptic DA receptors and the supply of
available DA in this disease.

Hornykiewicz (1975) reported

that increased activity of dopaminergic neurons may occur in
Parkinsonism as a compensation for the decrease of available
DA at the receptor.
Altered function of mesolimbocortical DA system has
been implicated in the pathophysiology of schizophrenia.
The disease was once considered to be related to a relative
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excess of central dopaminergic neuronal activity, in view of
the conviction that antipsychotic agents act therapeutically
through blockade of central DA transmission (Matthysse,
1973; Snyder, 1982).

Increased brain dopaminergic activity

in schizophrenia could occur through several mechanisms such
as increased synthesis and release of DA or altered
sensitivity of DA receptors (Losonczy et al., 1987).
Tardive dyskinesia, characterized by involuntary mouth
movements, tongue fibrillation and thrusting, occurs in some
patients who have been taking neuroleptics for long periods.
This motor disturbance is believed to result from
compensatory supersensitivity of striatal DA receptors
(Klawans, 1973).

Gilles de la Tourette' syndrome is

characterized by childhood onset of chronic motor tics and
involuntary vocalization.

The often dramatic response to

treatment with haloperidol, a DA Dz antagonist, the
similarity of the movements to those seen in patient with LDOPA intoxication and the disturbed decrease in DA
metabolism (Snyder et al., 1970; Butler et al., 1979), have
suggested that excessive DA transmission may have occurred
in the syndrome.

Likewise, changes in DA receptor binding

and coupling have been reported in Huntington's disease
(Reisine et al., 1977; Cross and Rossor, 1983; De Keyser et
al., 1989), which is a genetically determined neurological
disorder, and associated with a progression of involuntary
choreiform movements, psychological change and dementia.
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Lesch-Nyhan disease, which is associated with an inborn
deficiency of the enzyme hypoxanthine-guanine phosphoribosyl
transferase (Seegrailler et al., 1967) and characterized by
choreoathetoid movement and hypertonicity (Lesch and Nyhan,
1964; Wilson et al., 1983), has been found to be related to
reduced brain DA in children (Lloyd et al., 1981).

Because

treatment of neonatal rats with 6-OHDA resulted in increased
susceptability for self-mutilation behavior due to the
destruction of dopaminergic neurons, this useful
neurochemical model has been proposed for screening of a
variety of pharmacological agents that could minimize the
self-mutilation behavior observed in Lesch-Nyhan patients
(Breese et al., 1984; Breese et al., 1985a,b).

5-HTr Receptor-Related Animal Behaviors and Clinical
Implications
Recent evidence suggests that although 5-HT,c receptors
are at high density in the choroid plexus, they are widely
distributed in the brain and that their activation may have
numerous behavioral and physiological effects.

They may

thus be implicated in a number of CNS disorders (Julius et
al., 1988; Holineaux et al., 1989; Mengod et al,, 1990).
1. Locomotor effects: A clear role of 5-HTlc in behavior has
not yet been established due to the lack of a specific
agonist for the receptor.

However, motor effects were

reported to be associated with the activation of 5-HT]C
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receptors.

The piperazine agonists TFMPP [l-(m-

trifluoromethylphenyl)piperazine), m-CPP [l-(mchlorophenyl)piperazine] and non-selective ligands, such as
MK 212 [6-chloro-2-(l-piperazinyl)pyrazine], dosedependently suppress spontaneous locomotor activity in rats
(Kennett and Curzon, 1988a; Lucki et al., 19S9; Klodzinska
et al., 1989).

This effect was found to be prevented only

by 5-HT antagonists with high affinity for 5-HTtc receptors,
such as metergoline and mianserin, suggesting specific
involvement of these receptors.
2. Feeding: Systemic administration of m-CPP and TFMPP
reduces food intake in freely feeding rats (Kennett et al.,
1991).

Studies with 5-HT antagonists suggested that this

hypophagic effect is mediated by activation of 5-HT,c
receptors, though activation of 5-HTtB sites was also needed
for the response to occur (Kennett and Curzon, 1988b).
Dourish et al. (1989) proposed that postsynaptic 5-HTtc
receptors located in the ventromedial hypothalamus play an
important role in regulating feeding.
3. Psychiatric disorders: Administration of m-CPP in normal
human volunteers has been reported to increase feelings of
anxiety, dysphoria and panic (Charney et al., 1987; Murphy
et al., 1989).

Anxiogenesis was indicated by both decreased

social interaction and decreased activity in rats (Kennett
et al., 1989).

These effects might be related to 5-HT]c

receptors, because they are blocked by mianserin,

metergoline and cyproheptadine (i.e., compounds with high
affinity for the 5-HT,c receptor) .
4. Hypertonic saline consumption: Administration of
fenfluramine, fluoxetine, m-CPP, or MK 212 decreases
hypertonic saline intake at doses that have negligible
effects on water or physiological saline consumption (Neil
and Cooper, 1989).

Since the more selective 5-HT,,, agonist

CGS 12066B (7-trifluoromethyl-4(4-ethyl-l-pipera2inyl)pyrrolofl,2-alquinoxaline] has no such an effect, 5-HT,c
receptors have been suggested to be involved in mediating
salt-drinking behavior.

Further pharmacological

characterization of this effect is necessary.
5. Migraine effect: Recent evidence indicates that
ergotamine and dihydroergotamine, two effective antimigraine
agents, are potent 5-HT,c receptor antagonists in piglet
choroid plexus (Brown et al., 1991).

Therefore, it is

suggested that 5-HT,c receptors may play a role in
initiating migraine attacks (Fozard and Gray, 1989).
The above findings of so many potential roles for 5HT,C receptors suggest that the effects of many drugs acting
on brain 5-HT systems might have been targeting on these
particular receptor sites.

The availability of more

selective tools will clarify the roles of 5-HT,c receptors
in behavior and in CNS diseases.
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Rational*
The availability of 6-OHDA to destroy brain DAcontaining neurons in both adult and neonatal rat provides a
pharmacological means to study motor functions and lesionrelated biochemical changes that may depend on the age at
which the dopaminergic pathway is destroyed (Breese and
Traylor, 1970, 1972; Smith et al., 1973; Breese et al.,
1984, 1985b).

Treatment of adult rats with 6-OHDA produces

a profound motor dysfunction such as aphagia, adipsia and
akinesia (Breese and Traylor, 1970; Ungerstedt, 1971c;
Zigmond and Strieker, 1973).

In contrast, neonatal

treatment of rats with the toxin does not result in such an
acute motor syndrome despite the fact that near-total
destruction of this emerging DA system is produced (Erinoff
et al., 1979; Bruno et al., 1986; Duncan et al., 1987).
However, these rats exhibit an increased susceptibility for
self-mutilation behavior (Breese et al., 1984, 1985a,b).
Clinically, Parkinson's disease is associated with
reduced brain DA and motor dysfunction (Hornykiewicz, 1973),
and Parkinsonian patients display tremor, bradykinesia and
rigidity.

Another disorder related to the same brain

biochemical difficiency is Lesch-Nyhan syndrome.

The latter

syndrome is characterized by choreoathetoid movement,
hypertonicity and unique compulsive self-mutilation of
digits and tissue about the mouth (Lesch and Nyhan, 1964).
It is believed that the adult 6-OHDA-treated rat serves as a
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neurochemical model for Parkinson's disease (Ungerstedt,
1971), whereas the neonatal lesioned rat provides a model
for central dysfunctions observed in childhood diseases, one
of which is Lesch-Nyhan syndrome (Breese et al., 1984,
1985a,b).
Neonatal 6-OHDA-lesioned rats are also known to be
supersensitized to DA D, receptor agonists in the absence of
an altered density and affinity of the receptor.

SKF 38393,

a selective D, agonist, produces marked changes in
stereotyped and locomotor behaviors in the neonatal lesioned
rats (Breese et al., 1984, 1985a,b, 1987).

This change in

sensitivity is a latent one, which must be unmasked by
repeated doses of SKF 38393.

This is referred to as a

'priming' phenomenon (Criswell et al., 1989).

Priming of

neonatal 6-OHDA-lesioned rats has been implicated in
learning, development of craving following repeated intake
of some drugs, or the appearance of motor disturbances
following prolonged administration of drugs that influence
dopamine receptor functions (Criswell et al., 1989, 1990).
Hamdi and Kostrzewa (1991) demonstrated that the D, receptor
could be ontogenetically sensitized by repeated treatments
with a D, agonist during development.

As in adult-primed

rats, there were enhanced D, agonist-induced stereotyped
behaviors in adulthood.

In order to further investigate

ontogenetic sensitization of neonatal 6-0HDA-treated rats
and examine its underlying biochemical association, the
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selective D, receptor agonist, SKF 38393, was used alone, or
in combination with neonatal 6-OHDA lesion during postnatal
ontogeny in this study.
This project was thus undertaken with the objective of
(1) assessing the degree or extent of ontogenetic
sensitization of neonatal 6-OHDA-lesioned rats by repeated
treatments of the animals with a DA D, agonist in
development

(2) investigating the status of dynamics of the

DA Dt receptors, such as high and low affinity binding sites
in the neonatal 6-OHDA-lesioned rat model, or in neonatal 6OHDA-lesioned rats repeatedly treated in postnatal ontogeny
with SKF 38393

(3) evaluating the association of D,

receptors with second messenger systems in the above animal
models, and also

(4) determining mRNA levels for D,

receptors in these rat models.
The above investigations can lead to a better
understanding of whether ontogenetic DA D, agonist
treatments modulate the behavioral responses in adult rats
that were lesioned neonatally with 6-OHDA.

These studies

would also resolve the problem of whether several
biochemical markers would be associated with the enhanced
behavioral responses generated by a neonatal chemical lesion
or combined neonatal lesion plus ontogenetic DA D, agonist
treatments.
Moreover, in neonatal 6-OHDA-lesioned rats, acute
treatment with a DA D, receptor agonist results in a great

potentiation of the incidence of oral activity, even though
the

and Kd for striatal Dj receptor binding do not

accompany the marked reduction in DA content (Kostrzewa and
Hamdi, 1991}.

It is likely that the enhanced oral response

in neonatal 6-OHDA-lesioned rats is due to supersensitized
D, receptors,

since the striatal DA depletion in neonatal

6-OHDA-treated rats is accompanied by elevation in 5-HT
levels (Breese et al., 1984; Stachowiak et al., 1984;
Luthman et al., 1987),

hyperinnervation of rostral striatum

by 5-HT-containing fibers (Berger et al., 1985; Snyder et
al., 1986), and upregulation of several 5-HT receptor
subtypes in striatum (Radja et al., 1993), it is reasonable
to study possible interactions between DA and 5-HT
neurochemical systems in the Dt supersensitized induction of
oral activity by using this animal model.
Another aim in the present project, therefore, was to
evaluate whether 5-HT receptors were involved in the
induction of supersensitized oral responses in neonatal 6OHDA-lesioned rats.

The piperazine compound, m-CPP, was

used in this study, because this 5-HT receptor agonist was
found to induce oral activity in intact rats (Stewart et
al., 1989).

A series of other 5-HT agonists and antagonists

was also used to determine which probable 5-HT receptor
subtype would be related to such involvement.

This study

should provide evidence of whether there is a functional
correlation between DA D, receptor and 5-HT fiber

innervation of the striatum.

Chapter 2
Materials and Methods

Animals and Treatment
Timed-pregnant Sprague-Dawley derived albino rats were
obtained from Charles River Laboratories (Research Triangle,
NC) approximately 1 week before delivery.

Animals were

housed singly in clear Perspex cages in a room with
controlled temperature (22 ± 1 °C) and lighting (12 h-12 h
light-dark cycle, lights on at 07:00), and had free access
to food and water.

Date of litter delivery was noticed

within 12 hours and the date of birth was considered as day
0.

At birth, litters were reassigned, so that each dam had

rats from several litters, with each reconstituted litter
consisting of a maximum of ten pups.
Starting at birth all pups were treated once a day for
28 consecutive days by intraperitoneal (i.p.) injection of
SKF 38393 HCl (l-phenyl-2,3,4,5-tetrahydro-[lH]-3benzazepine-7,8-diol hydrochloride; 3.0 mg/kg, salt form;
Research Biochemicals, Inc., Natick, MA) or saline vehicle.
At 3 days from birth all rats

also received a bilateral

intracerebroventricular (i.c.v.) injection of 6-OHDA
hydrobromide (100 /jg, salt form, on each side; Regis
Chemical Co., Chicago, IL) or the vehicle, saline-ascorbic
acid (0.1%).

Neonates were pretreated with desipramine (20

mg/kg i.p.) 1 hr before 6-OHDA injection to prevent
33
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destruction of noradrenergic neurons,

starting 3 days after

birth, all animals were divided into four treatment groups:
(1) saline (2) SKF 38393 (3) 6-OHDA (4) SKF 38393 plus 6OHDA.

At the age of 6 weeks, the first portion of the rats

from each group was challenged with SKF 38393, to study (1)
locomotor activity

and (2) stereotyped behaviors (see

behavioral observations). These rats were continuously
tested with a weekly challenge dose of SKF 38393 for another
three weeks.

At 9 weeks of age, a second portion of the

rats from all treatment groups without weekly challenge dose
of SKF 38393 in adulthood, was sacrificed for biochemical
analyses only.
At 3 and 9 months of age, another two separate groups
of rats consisting of neonatal saline and 6-OHDA treatment,
respectively, were used for determination of oral activity
response to DA D, agonist and antagonist as well as a series
of 5-HT receptor agents.
All animals were sacrificed by decapitation.

Brains

were immediately removed and the striata were dissected
free, quickly frozen on dry ice, and stored at -70 °c for
later in vitro neurochemical assessments (see biochemical
assays below).

Behavioral Observations
1. Locomotor activity.

Between 6 and 9 weeks of age, rats

were placed singly in donut-shaped test chambers (46 cm in
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diameter) with six equidistant markings along the
circumference. After a 60 min habituation period in a quiet
and well-lighted room, a challenge dose of SKF 38393 HCl
(3.0 mg/kg i.p., salt form) or vehicle was administered.
Locomotor activities were then videotaped by a camcorder for
60 min starting 10 min after the challenge agent.

Tapes

were replayed and the distance traveled by each rat was thus
determined.
2. Stereotyped behaviors.

At 8 weeks of age, rats were

placed singly in clear Perspex cages (48 x 26 x 18) with
wood chip bedding, in a quite and well-illuminated room, and
were acclimated to the testing surroundings for 30 min.

An

individual rat was challenged first with saline vehicle 10
min before behavioral testing.

The rat was then observed

for stereotyped behaviors for 10 min.
SKF 38393

A challenge dose of

HCl (3.0 mg/kg i.p., salt form) was then

administered and rats were again observed for 10 min for
stereotyped behaviors, starting 10 min after injection.
Behaviors were quantified as seconds in which each
particular behavior was performed by a rat.

Therefore, the

total time an individual rat spent in performing or not
performing an activity was 600 seconds (10 min observation
period).

The behaviors observed were locomotion, sniffing,

grooming, eating, taffy pulling (coordinated movement of
front paws toward the mouth and then away from the body),
digging, gnawing, licking, jumping, paw treading and

locomotion.

Yawning and rearing were counted as numbers of

incidents, not seconds.

Immobility was defined as the time

period in which a rat was not observed in any stereotypic
activity.
3. Oral activity: Rats were observed for oral responses to
test agents between 3 and 9 months of age.

For each test

session, rats were placed in individual clear plastic cages
(48 x 26 x 18 cm) with steel grid floors in a quiet, wellventilated and well-lighted room.

Rats were allowed to

acclimate to the new environment for at least 1 hr.
Between 9:00 A.M. and 4:00 P.M. each rat was given a
single i.p. or s.c. treatment with vehicle, SKF 38393 HC1
{0.03-3.0 mg/kg i.p.),* m-CPP 2HC1 [l-(3chlorophenyl)piperazine dihydrochloride, o.5-8.0 mg/kg
i.p.]; CGS 12066B maleate {7-trifluoromethyl-4(4-ethyl-lpiperazinyl)-pyrrolo[l,2-alquinoxaline], 1:2 maleate salt,
3.0 mg/kg i.p.}; or 8-0H-DPAT HBr [(±)-8hydroxydipropylaminotetralin hydrobromide, 0.1 mg/kg s.c.].
Each rat was then observed one at a time, for 1 min every 10
min, over a 60-min period, beginning 10 min after any of
these treatments.
counted.

Numbers of rapid jaw movements were

Some rats were pretreated with mianserin HC1 (1.0

mg/kg s.c., 30 min); ketanserin tartrate (5.0 mg/kg i.p., 30
min); MDL 72222 (3-tropanyl-3,5-dichlorobenzoate, 10.0 mg/kg
s.c., 30 min); or SCH 23390 HCl [R-(+)-7-chloro-8-hydroxy-3methyl-l-phenyl-2,3,4,5-tetra-hydro-lH-3-benzazepine
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hydrochloride, 0.30 mg/kg i.p., 1 hr].

At least 1 week

intervened between these observation sessions.
Oral activity in these studies is of the type described
by Haddington (1990) as "vacuous (or abortive or
spontaneous) chewing, whereby what appear to be robust
chewing sequences are manifested, but are not directed onto
any evident physical material."

No differentiation between

lateral and vertical jaw movements was made.

Also, there

was occasional tongue thrusting noted in the these rats.
Oral activity that occurred in eating, grooming or taffy
pulling was not counted.

petemination of Pa,_5-HT_*na_Thelr_Hetabolites in the
Striatum
Striatal concentrations of DA, 5-HT and their
metabolites were measured by liquid chromatography with
electrochemical detection as follows.

The striata were

sonicated in 1 ml of 0,1 H trichloroacetic acid containing
0.2 mg/ml cysteine as a stabilizing agent and an internal
standard which was 0.2 nmol/ml 5-hydroxyindole carboxylic
acid (5HICA).

The resulting homogenate was centrifuged at

12,000 x g for 5 min and DA, homovanillic acid (HVA), 3,4dihydroxyphenylacetic acid (DOPAC), 5-HT and 5hydroxyindoleacetic acid (5-HIAA) were assayed by injecting
30 nl of supernatant directly onto the C18 analytical
column.

The column was an Econosphere CIS (5 micron, 4.6 x
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150 ram) from Alltech Associates.

The mobile phase was 0,1 M

monochloroacetic acid, 1 raM EDTA, 220 mg/1 sodium
octanesulfonic acid, 8% acetonitrile, pH 2.6 at a flow rate
of 1.3 ml/min and temperature of 40 °C.
The instrumentation consisted of a Bioanalytlcal System
LCEC Analyzer and a Waters WISP automatic sample injector
with a refrigrated sample compartment (samples kept at 5°C).
The glassy carbon electrode was used at a potential of +0.75
volts.

Peak heights and sample concentration were

calculated with a Hewlett-Packard HP1000 chromatography data
system.

Determination of

da

competition for f^iscH 23390 Binding to

striatal Homogenates
To assess DA competition for [3H]SCH 23390 binding, a
modified method of Hess et al. (1986) was used.

Briefly,

striata were homogenized with a Teflon on glass mortar and
pestle, in 100 volumes of ice cold 50 mM Tris buffer (pH
7.4).

This gentle homogenizing procedure was used to avoid

destruction of Dt receptors during this tissue preparation
step (Norman et al., 1989).

Homogenates were then

centrifuged at 35,100 x g for 10 min at 4 °C using a Beckman
J2-21M centrifuge and JA-20.1 rotor.

After one wash, the

homogenates were preincubated at 37 °c for 15 min, chilled
in ice and centrifuged as before.

Tissue pellets were

finally resuspended in 200 volumes of fresh buffer.

Aliquots (300 pi) of homogenates were added to 450 pM
of [3H]SCH 23390 (specific activity 294 mCi/mg; Amersham,
Arlington Heights, IL) in Tris buffer containing 120 mM
NaCl, 5 mM KCl, 2 mM CaCl2, 0.1% ascorbic acid, 10 pM
pargyline (final concentrations) and varying concentrations
of DA as competitor (1 nM - 1 mM), to yield a 2.5 ml final
assay volume.

Samples were incubated for 40 min at 37 °C in

a shaking water bath, and then were rapidly filtered under
partial vacuum on Whatman GF/F glass fiber filters using a
Millipore filtration unit.

Filters were washed 3 times with

5 ml of ice-cold Tris-salt solution each time.

After drying

overnight, filters were placed in 9 ml of fluor, and tritium
activity was determined in a Beckman LS 9800 liquid
scintillation spectrometer.

A GraphPad program (GraphPad

Software Inc., San Diego, CA), using a nonlinear regression
model for complex ligand-receptor binding systems, was used
to fit the agonist-antagonist competition curves matching
two binding sites.

The ICjo values for DA at the high and

low affinity site and the percentage of each receptor
binding component were estimated by the computer program.
The K, for each ICi0 was determined according to following
equation:
ICm
K,

=

--------------

1 + L / Kj
where L is the concentration of [JH]SCH 23390 and Kd is its
affinity for the receptors.
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Determination of mRNA Levala for Pt and 5-HT,,. Receptors in
the Striatum
Two mixtures of 48-base oligonucleotide probes for the
respective rat DA D, and 5-HT,c receptor mRNA were used (NEN
Research Products, Boston, MA). The sequences for D(
receptor mRNA are complementary to bases 13-60 (5'-GAA ATC
CCT CTC CGC TGG CAG CCC GGC CTC ATC CAT

GGT AGA AGTGTT-3'),

520-567 (5/-GGA CTG CTG CCC TCT CCA AGG

CTG AGA TGC CCC GGA

TTT GCT TCT GGG-3') and 664-711 (5'-TGT CAC ACT TGT CAT CCT
CGG TGT CCT CCA GGG AGG TAA AAT TGC CAT-3'), while the
sequences for 5-HTlc receptor mRNA are complementary to
bases 4-51 (5'-GCC GAT TAG GTG CAT CAG GAG CGA GCG CAC CGC
GTT GCC AAG GTT CAC-3'), 721-768 (5'-CTC CTC GGT GTG ACC TCG
AAG TAA CAT CAG AGT TTG ACG GCG CAG GAC-3')
GGT GCC TCT GGG ACG CTT TTG TTT CTT CTT

and 856-903

(5'-

TCG ACG TGG TTT CTG

ATC-3').
Rat striatal tissues from above treatment groups were
homogenized in denaturing solution containing 4.0 M
guanidine thiocyanate, 42 mM sodium citrate, 0.83% N-lauroyl
sarcosine and 0.2 mM B-mercaptoethanol, using a Tekmar
Tissuraizer (setting 5, 20 sec).

After adding 2.0 M sodium

acetate (pH 4.0), the homogenates were extracted with equal
volume of phenol:chloroform:isoamyl alcohol mixture and then
centrifuged at 10,000 x g (20 min at 4 °C).

The upper

aqueous phase was collected and the total RNA was
precipitated with isopropanol by centrifugation.

RNA was
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quantified by UV spectrophotometry at 260 nm wavelength.
A sample representing 5-10 fig of striatal RNA denatured
at 95 °C for 2 min, was fractionated by electrophoresis on
1% agarose gel containing 2% formaldehyde, 20 mM 3-(Nmorpholino)propanesulfonic acid, 5 mM sodium acetate and 1
mM EDTA.

The gel was stained with ethidium bromide and

visualized under UV light to check the integrity and loading
of the RNA in each lane.

The RNA was then transferred to

nylon membranes (Schleicher & schuell, Keene, NH), which
were subsequently crosslinked under UV light for 5 min and
baked at 80 °C for half an hour.

Some of the striatal RNA

samples from each treatment group were denatured in 7.4%
formaldehyde at 65 °C and then transferred directly to nylon
membrane on an apparatus for dot blot analysis.

The

membranes were probed with respective D, and 5-HTlc receptor
mRNA probe according to following procedure.
Membranes were incubated for l hr at 58 °C in 20 ml of
prehybridization buffer containing 5 x SSC, 20 mM Na2HP04, 7%
SDS, l x Denhardt's solution and 100 fig/ml denatured salmon
sperm DNA.

Following prehybridization, the buffer was

replaced with the same new fresh buffer and the membranes
were hybridized with oligonucleotide probes at 58 °C for 24
hr, which were end-labelled with [r-HP]ATP using
oligonucleotide 5'-end labelling system (Promega
Corporation, Madison, WI).

The membranes were washed twice

in 2 x SSC, 1% SDS and 20 mM Na2HP04 at room temperature for

15 rain.

They were finally washed twice in 0.5 x SSC and 1%

SDS at 58 °C for 15 min and then were exposed to Kodak XOMAT AR film (Sigma Chemical Co., St. Louis, MO} at -70 °C
with two intensifying screens for 48-72 hr to ensure that
the exposure time was within the linear range of the film.
The optical densities of the bands or the dots were measured
by a Bio Image Analysis system (Millipore Corporation
Imaging systems, Ann Arbor, MI).

The probes were removed

from the membranes by washing in solution containing 50%
formamide and 2 x SSPE buffer at 65 °C for 1 hr before
rehybridization with cDNA probe for B-actin mRNA.

The B-

actin mRNA probe was labelled with [a-JIP]dCTP by a Prime-aGene labelling system (Promega Corporation, Madison, WI) to
give a specific activity of 1-2 x 109 cpm per fig of DNA.
The B-actin mRNA measurements were used mainly for
correcting errors that occurred in preparation or loading of
the RNA samples.

Determination of DA-fltimulated Adenvlate Cyclase Aetivitv in
the Striatum
The striatal tissues from all above treatment groups
were homogenized with a Teflon on glass mortar and pestle,
in 50 volumes of ice-cold 10 mM Tris maleate/2 mM EGTA
buffer (pH 7.4).

Homogenates were then centrifuged at

35,100 x g for 10 min in Beckman model J2-21M superspeed
centrifuge, using a JA-20.1 rotor.

After one wash with the
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same buffer and centrifugation as before, the resultant
pellet was resuspended in 70 volumes of fresh buffer and
kept on ice prior to use for adenylate cyclase activity
assays.
Adenylate cyclase activity was assayed in a 200-jil
incubation mixture containing 80 mM Tris maleate, 0.4 mM
EGTA, 4.0 mM MgS04, 1.0 mM isobutylmethylxanthine, 5.0 mM
phosphocreatine, 50 unit/ml creatine phosphokinase, 0.02%
ascorbic acid, 10 juM pargyline, 0.1 mM GTP, 50 nM spiperone,
and varying concentrations of DA (0-10° M).

In some

instances, 12.2 /iM forskolin or 10 mM NaF in combination
with 10 jiM Alcl3 ([A1F4)‘), was added to the mixture instead
of DA, in order to stimulate the catalytic subunit of the
enzyme or the Ns protein, respectively.

Spiperone was

included in all incubation solutions to block DA D2
receptor-mediated inhibition of adenylate cyclase activity.
Membrane suspensions (30-40 /ig protein) were preincubated at
30 °C for 5 min in the reaction mixture.

The reaction was

then started by adding ATP (final concentration: 1.0 mM) and
the mixtures were incubated at 30 °c for 15 min.

After

termination of the reaction in boiling water for 4 min, the
mixtures were centrifuged at 13,000 x g for 5 min.

Aliquots

of the supernatant were assayed for cAMP content using an
Amersham cAMP enzymeimmunoassay kit (RFN 225, Amersham, UK;
sensitivity: 38.4 pg/ml).

Protein content of striatal

homogenates was determined by the method of Lowry et al.
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(1951).
Data Mialvaia
Locomotor activity: Data are expressed as the mean
distance (meters) ± S.E.M. in different groups of rats
traveling within activity testing chambers.

The statistical

significance of the data was determine by a two-way analysis
of variance (ANOVA), followed by a post-ANOVA Newman-Keuls
test.

A p value of < 0,05 was considered to be

statistically significant.
Stereotyped behaviors: Results are expressed as the
mean time (seconds) ± S.E.M. in which rats from different
treatment groups perform a particular behavior.

The

statistical significance of the results was evaluated by a
one-way ANOVA, followed by a post-ANOVA Newman-Keuls test. A
p value of < 0.05 or smaller was considered to be
statistically significant.
Oral activity: Results are expressed as the mean number
of oral movements ± S.E.M. of rats receiving neonatal 6-OHDA
treatment or vehicle.

The statistical significance was

determined by a one-way ANOVA, followed by a post-ANOVA
Newman-Keuls test.

A p value of < 0.05 or smaller was

considered to be statistically significant.
Monoamine determinations: The mean nanomoles of
monoamine or metabolite per gram of tissue ± S.E.M. in
different treatment groups were analyzed by the ANOVA,
followed by a post-ANOVA Newman-Keuls test, in order to
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determine the statistical significance among treatment
groups.

A p value of < 0.05 was considered to be the level

for statistical significance.
Binding studies: Competition curves were analyzed
according to models for the competition of radioligand and
competitor, DA, to one or two binding sites.

The

statistical difference between models was tested by
comparing the sum of squares which resulted from different
fits of the data.

A sequential F-test was used according to

the following equation:
SS, - SS,
F =

df, - df,
------------

ssa
df,

where SS refers to the sum of squares, and df refers to the
number of degree of freedom.

The subscrit 1 and 2 refer to

the model for one, and two binding sites, respectively.

A

model for two binding sites was retained only when it fitted
the data statistically significantly better than a model for
one binding site (p < 0.05).

Also, the mean (+ S.E.M.)

percent of high affinity binding sites (%RH), and the
respective mean (± S.E.M.) KH and KL in each treatment group
were analyzed by one-way ANOVA.

A p value of < 0.05 was

considered to be the level for statistical significance.
mRNA analyses and adenylate cyclase activity assays:
The mean {± S.E.M.) ratio of D( or 5-HTIC receptor mRNA to JJ-
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actin mRNA, and mean (± S.E.M.) picomoles of cAMP per
milligram of protein per min, respectively, were analyzed by
ANOVA, followed by a post-ANOVA Newman-Keuls test, in order
to evaluate the statistical significance among different
treatment groups.

A p value of < 0.05 was considered to be

the level for statistical significance.

Chapter 3
Results

DA D1 Receptor Bupersensltlvitv

Locomotor activity of rats
Starting at 6 weeks adult rats from the different
treatment groups were tested at weekly intervals for
spontaneous and SKF 38393-induced locomotor activity.

At 6,

7 and 9 weeks there was little locomotor activity in each
group after administration of saline, and no statistically
significant difference between the groups (p > 0.05, left 4
bars in figs. l, 2 and 3).
At 6 , 7 and 9 weeks, SKF 38393 HC1 treatment (3.0 mg/kg
i.p.) did not increase locomotor activity in the vehicle
control rats, nor in the rats treated repeatedly during
development with SKF 38393 HCl (3.0 mg/kg per day x 28 days
from birth, i.p.; Fig. 1, 2 and 3, 5th and 6th bars).

At 6

weeks acute SKF 38393 HCl treatment (3.0 mg/kg i.p.)
produced a slight increase in locomotor activity in the
group of rats that was lesioned at 3 days after birth with
6-OHDA HBr (200 jig, i.c.v.), although this effect was not
different from that after saline treatment (fig. 1, 7th
bar).

However, in the group of rats that was both lesioned

at 3 days after birth with 6-0HDA and treated repeatedly in
development with SKF 38393 HCl (3.0 mg/kg per day x 28
47
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days), acute SKF 38393 treatment at 6 weeks produced a large
increase in locomotor activity (p < 0.05, fig. 1, 8th bar).
Rats in this group traveled about 210 meters in 1 hr, vs.
about 40 meters for the 6-OHDA-lesioned group (p < 0.05, 8th
vs. 7th bar of fig. 1).

The greater SKF 38393-induced

activity in this group suggests that ontogenic SKF 38393
treatments produced homologous sensitization of the DA
receptors.
One week later when rats were challenged again with SKF
38393, there was an increase in locomotor activity in the 2
groups of rats lesioned at 3 days after birth with 6-OHDA.
In the group treated at 3 days with 6-OHDA, locomotor
activity increased substantially from one week before, now
155 meters in the one hour following the challenge dose of
SKF 38393.

In the group that was lesioned with 6-OHDA at 3

days and also treated repeatedly in development with SKF
38393, the challenge dose of SKF 38393 at 7 weeks increased
the distance traveled to more than 590 meters, nearly triple
that from the week before (8th bar of fig. 2 vs. 8th bar of
fig. 1).
In the 8th week rats were tested for stereotyped
activities following the SKF 38393 injection, so there is no
locomotor activity data.

In the 9th week the challenge dose

of SKF 38393 produced more than a 2-fold increase in
locomotor activity in the group of rats lesioned at 3 days
after birth with 6-OHDA (p < 0.05, 7th bar of fig. 3 vs 7th
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bar of fig. 2).

However, in rats receiving both 6-OHDA and

SKF 38393 treatments in development, the challenge dose of
SKF 38393 at 9 weeks increased the distance traveled only
slightly and not significantly from that at 7 weeks (8th bar
of fig. 3 vs. 8th bar of fig. 2).

Nevertheless, SKF 38393-

induced locomotor activity in this group was higher at 9
weeks vs. 6 weeks (p < 0.05, 8th bar of fig. 3 vs. 8th bar
of fig. 1).

Stereotyped behaviors of rata

At 8 weeks, following a saline injection, there was
little stereotyped activity in the 4 groups of rats, with
immobility time being 340 to 490 seconds (i.e., 600 seconds
of observation, table 1 ).

Following the challenge dose of

SKF 38393 HCl (3.0 mg/kg i.p.) activity increased in all
groups (table 2).

However, for rats treated repeatedly in

development with SKF 38393, there was no difference from
control for time spent in sniffing, locomotion, grooming,
eating, taffy pulling, digging, gnawing and paw treading,
following the challenge dose of SKF 38393 at 8 weeks.

Also,

numbers of yawns and rearings was not different between
these two groups.
In the group of rats lesioned at 3 days with 6-OHDA,
the challenge dose of SKF 38393 at 8 weeks substantially
increased time in locomotion (351.7 ± 59.6 vs. 1.7 ± 0.9
sec) and paw treading (89.0 ± 50.2 vs. 0.0 sec), compared to
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the vehicle control group (all p < 0.05, table 2).
Conversely, in the 6-OHDA vs. control group, the challenge
dose of SKF 38393 decreased time in grooming (4.3 ± 4.3 vs.
135.4 ± 21.8 sec), gnawing (1.1 ± 0.7 vs. 12.1 ± 2.3 sec)
and immobility (84.1 ± 56.3 vs. 396.1 ± 34.4 sec) (all p <
0.05, table 2).
In the group of rats lesioned at 3 days with 6-OHDA and
also treated daily for the first 28 days from birth with SKF
38393 HCl (3.0 mg/kg per day, i.p.), the challenge dose of
SKF 38393 at 8 weeks produced several changes in stereotyped
behaviors.

Time in locomotion (228.9 ± 74.8 sec), taffy

pulling (172.5 ± 87.8 sec) and paw treading (140.3 ± 75,8
sec) was increased vs. the control group (p < 0.05); taffy
pulling was different vs. the 6-OHDA group (p < 0.05, table
2).

Time in grooming (3.5 ± 3.5 sec) and immobility

(0.0

sec) were different vs. control (p < 0.05); while immobility
time was different vs. the 6-OHDA group (p < 0.05).

Striatal levels of DA. DOPAC. HVA, 5-HT and 5-HIAA

As shown in table 3, neonatal 6-OHDA treatment produced
a profound depletion of DA (>99% reduction), DOPAC (>99%
reduction) and HVA (>99% reduction) in the striatum of rats.
Conversely, neonatal 6-OHDA treatment was associated with a
70% increase in striatal 5-HT and 35% increase in 5-HIAA
content (all p < 0.001).

SKF 38393 treatments for the first

28 days after birth did not produce an effect on striatal
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levels of DA, 5-HT and their metabolites, nor did this
treatment modify the effect of 6-OHDA.

Agonist competition for PA D1 receptor binding in striatal

baBpq<nn**g
Computer-modeled DA agonist-[sH]SCH23390 antagonist
competition binding curves are shown in figs. 4-7 for the
respective groups receiving saline, ontogenetic SKF 38393
and/or neonatal 6-OHDA treatments.
site model.

Each curve fits a two-

Dissociation constants to high affinity (RH)

and low affinity (RL) have been designated KH and KL,
respectively.

Table 4 summarizes computer-assisted binding

parameters for DA competition curves, demonstrating that
these curves exhibit high and low affinity binding
components.

No apparent difference was observed in the

distribution of high and low affinity agonist binding sites
between 6-OHDA vs. saline group.

Also, there was no

significant effect of ontogenetic SKF 38393 treatments on
the affinity of DA at either high or low affinity states of
the receptor.

Postnatal treatment of 6-OHDA lesioned rats

with SKF 38393 for 28 consective days likewise did not
affect high or low affinity agonist binding sites.

Striatal levels of DA Dl receptor mRNAs
Dot blot analysis revealed that in the first portion of
rats that did not receive weekly challenge doses of SKF
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38393 in adulthood, striatal mRNA levels for DA D, receptor
were significantly reduced (p < 0.05) in neonatal 6-0HDAlesioned rats, regardless of whether ontogenetic SKF 38393
treatments were given (fig. 8A).

SKF 38393 treatments for

the first 28 days after birth per se did not produce an
effect on striatal mRNA content of the D, receptor (fig.
8A).

In the second portion of rats receiving weekly adult

challenge doses of SKF 38393, the striatal mRNA levels for
D, receptors in neonatal 6-OHDA-treated rats were restored
to the control level, so that there was no statistically
significant difference in D, receptor mRNA content among the
treatment groups (fig. 8B).

Striatal DA-atimulated adenylate cyclase activity
No significant difference in basal adenylate cyclase
activity was observed between treatment groups (fig. 10).
Stimulation of D( receptors by DA significantly increased
adenylate cyclase activity in the striatum at higher doses
of DA (lO^-lO*1 M) in all treatment groups.

The relative

increase among saline, SKF 38393, 6-OHDA, and /SKF 38393 +
6-OHDA' treatment groups was similar (fig. 9).

To evaluate

the effects of neonatal 6-OHDA and ontogenetic SKF 38393
treatments on the receptor coupling with G-protein, NaF was
used to stimulate Ns.

The adenylate cyclase activity was

enhanced by NaF, but there were no statistical differences
among the treatment groups (fig. 10, p=0.05l).

To examine
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the effects of neonatal 6-OHDA and ontogenetic SKF 38393
treatments on the activity of adenylate cyclase, the enzyme
was stimulated directly with forskolin.

The activity of

adenylate cyclase was markedly increased by forskolin.
However, no significant difference was found in the
treatment groups of saline, SKF 38393, 6-OHDA, and SKF 38393
plus 6-OHDA (fig. 10, p=0.759).

Mediation of PA Agonist-induced Oral Behavior
bv the Serotonin System

Dose-response study of SKF 38393-induced oral activity
To determine the optimal doses of SKF 38393 for
inducing oral activity, a dose-response curve was
constructed (fig. 11).

In the saline control group, SKF

38393 at a dose of 0.1 mg/kg and higher resulted in only a
slight increase in oral activity.

In the 6-OHDA group, the

threshold dose of SKF 38393 was 0.03 mg/kg, with oral
activity increasing to 15 ± 2.9 movements (p < 0.01).

At

higher doses of SKF 38393 there were about 40 oral movements
during the session (p < 0.005).

Effect of combined D1 aoonlat and D1 antagonist treatments
To determine whether a DA D1 receptor antagonist would
attenuate the oral responses of rats to a D1 agonist, rats
were treated with

sch

23390 (0.3 mg/kg, i.p.) 1 hr before
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SKF 38393 (0.3 mg/kg, i.p.}*

As shown in fig. 12, SCH 23390

attenuated the action of SKF 38393 (p < 0.005), indicating
that SKF 38393-induced oral activity is a Dl-receptormediated event.

Dose-responsa study of m-CPP-lnduced oral activity
To determine the optimal dose of m-CPP for induction of
the oral response, a series of doses of m-CPP was
administered to rats.

As shown in fig. 13, the oral

response was increased in both the control and 6-0HDAlesioned groups of rats after m-CPP

doses inthe range of

0.5 to 8.0 mg/kg i.p..

responsewas greater in

The overall

the 6-OHDA vs. the control group of rats (p < 0.001), with
the apparent maximal response in the 6-OHDA-lesioned rats
occurring at the 4.0 mg/kg dose of m-CPP.

Effects of S-HT1A and 5-HT,P receptor

agonistson oral

activity
To determine the possible involvement of 5-HT(
receptors on induction of oral activity, rats were treated
with either the 5-HTtA receptor agonist, 8-OH-DAPT HBr (0.1
mg/kg s.c., 10 min before observation) or the 5-HT,0
receptor agonist, CGS-12066B maleate (7-trifluoromethyl-4(4methyl-l-piperazinyl)pyrrolo[l,2-alquinoxaline], 1:2 maleate
salt, 3.0 mg/kg i.p., 10 min before observation).

As shown

in fig. 14, 8-OH-DPAT did not induce an oral response in
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rats.

Also, CGS-12066B did not produce a statistically

significant increase in oral activity in control and 6-OHDAlesioned rats (fig. 14}.

Effects of 5-HT receptor antagonists on m-CPP-lnduced oral
activity
To assess whether m-CPP might produce enhanced oral
activity through an action on several different types of 5HT receptors, a variety of 5-HT receptor antagonists were
administered in conjunction with m-CPP (1.0 mg/kg i.p.).
After pretreatment with mianserin (1.0 mg/kg s.c.), a mixed
antagonist for 5-HT)c and 5-HT2 receptors, there was complete
attenuation of the oral response to m-CPP (p < 0.001, fig.
15).

Ketanserin (5.0 rag/kg i.p.), a relatively selective

antagonist for the 5-HT2 receptor, failed to modify the oral
response to m-CPP (fig. 15).

Similarly, MDL 72222 (10.0

mg/kg s.c.), a relatively selective antagonist for the 5-HT3
receptor, failed to alter the response to m-CPP (fig. 15).

Effect of a DA D, receptor antagonist on m-CPP-lnduced oral

To determine whether a DA Dt receptor antagonist would
attenuate the oral response of rats to the 5-HT agonist, mCPP, rats were treated with SCH 23390 (0.3 mg/kg i.p.).

As

shown in fig. 16, SCH 23390 failed to attenuate the enhanced
oral response to m-CPP, indicating that 5-HT agonist-induced
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oral activity is not mediated through the DA p! receptor.

Effect of a 5rHTir receptor antagonist on

da

D,_acrQnlgt^

induced oral activity
To determine whether a 5-HTiC receptor antagonist would
attenuate the oral response to a DA D, receptor agonist,
rats were treated with mianserin (1.0 mg/kg s.c.) 30 min
before SKF 38393 (1.0 mg/kg i.p.).

As shown in fig. 17,

pretreatment with mianserin attenuated the enhanced oral
response to SKF 38393, in both control (p < 0.05) and 6OHDA-lesioned rats (p < 0.001),

This finding indicates that

the oral response of rats to a D( agonist is mediated via a
5-HT system involving 5-HTJC receptors.

Effect of neonatal 6-OHDA treatment on concentrations of_PA^
5-HT and their metabolites in the striatum
As expected, neonatal 6-OHDA treatment profoundly
reduced striatal DA, HVA and DOPAC contents (>98% reduction,
p < 0.001; table 5).

Accompanying this change was an

elevation in striatal 5-HT content by 77% (p < 0.001), and a
slight but not statistically significant increase in 5-HIAA
content (table 5).
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Effect of neonatal 6-QHPA and ontogenet_ic_8KF_3a393
treatmentg_on mRNA levels for B-HT^ recaptors of the
striatum
To evaluate the effect of neonatal 6-OHDA and
ontogenetic SKF 38393 treatments on 5-HTlc receptor gene
transcription, dot blot analysis was also employed.

There

was no significant difference in the mRNA levels for 5-HT,c
receptors in the striatum between neonatal 6-OHDA-lesioned
and intact rats (fig. ISA).

Ontogenetic treatments of

either intact or lesioned rats with SKF 38393 did not alter
the mRNA level for the 5-HTlc receptor (fig. 18A). After
repeated administration

of SKF 38393 in adulthood, there

was still no change in 5-HT(C receptor mRNA in saline, 6OHDA, SKF 38393, and 'SKF 38393 + 6-OHDA' treatment groups
(fig. 18B).
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TABLE 1
Behavioral effects of acute saline challenge in rats treated
developmentally with SKF 38393 or saline, in combination with
single i.c.v. injection of 6-OHDA or its vehicle.

Group
Behavior

Saline

Sniffing

SKF 38393

49.7 ± 10.7

Locomotion

1.5 ±

1.0

38.2 ± 12.1

Grooming
Eating

174.0 ± 50.6
5.2 ±

6-OHDA

6-OHDA + SKF

66.8 + 34.3

93.6

± 25.0

2.6

1.7 ± 0.9

3.0

37.4 ± 24.7

21.6 + 7.8

57.6

± 31.4

26.4 + 16.1

7.5 ± 4.7

10.1

±

4.8

0.0

±

0.0

±

1.2

4.2 ±

4.2

Taffy pulling 0.0 ±

0.0

0.0 ±

0.0

0.0 ±

0.0

Digging

1.0 ±

0.4

1.8 ±

1.2

0.8 +

0.4

1.1 ±

0.6

Gnawing

6.5 ±

0.9

7.8 ±

3.1

13.4 +

2.8

15.2 ±

2.6

Paw treading

0.0 ±

0.0

0.0 ±

0.0

0.0 +

0,0

0.0 ±

0.0

Yawning'

0.3 ±

0.3

0.0 ±

0.0

0.6 +

0.3

0.2 ±

0.1

Raring'

5.6 ±

2.3

10.2 ±

3.8

5.3 +

2.9

3.8 ±

1.4

Immobility

493.0 ± 20.7 337.2 :t 64.2

482.3 ± 38.6

414.9 ± 36.2

Behavioral activity was determined in rats that were treated during
postnatal development with a DA D, agonist, SKF 38393 HCl (3.0 mg/kg
per day x 28 days, i.p., from day of birth and/or the catecholamine
neurotoxin 6-OHDA HBr (200 /ig i.c.v., salt form, at 3 days from
birth; desipramine pretreatment, 1 hr). Rats were challenged with
saline at 8 weeks from birth and were immediately observed for
stereotyped behaviors for 10 min. Behaviors were thus quantified
as seconds in which each individual behavior was performed by a
rat. The total observation time was 600 seconds.
lYawning and
rearing behaviors were counted as numbers of incidents, not
seconds. Each group is the mean of 10 rats.
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TABLE 2
Behavioral
effects
of
acute SKF
38393
in rats
treated
developmentally with SKF 38393 or saline, in combination with
single i.c.v. injection of 6-OHDA or its vehicle.

Group
Behavior
Sniffing
Locomotion
Grooming
Eating

Saline

SKF 38393

49.5 ± 14.2
1.8 ±

0.9

135.4 ± 21.8
0.5 ±

Taffy pulling 0.0 ±

95.2 ± 24.0
0.8 ±

0.5

95.6 ± 22.0

6-OHDA
22.8 ±

6-OHDA + SKF
7.6

54.8 ± 34.6

351.7 ± 59.6* 228.9 ± 74.8*
4.3 +

4.3*

3.5 ±

1.8 ±

1.0

0.0 ±

0.0

0.0

0.0 ±

0.0

0.0 i

0.0 172.5 ± 87.8*+

0.5

0.0 ±

3.5*
0.0

Digging

0.4 ±

0.3

2.1 +

1.2

2.3 ±

1.9

0.0 ±

0.0

Gnawing

12.1 ±

2.3

7.7 ±

1.8

1.1 ±

0.7*

0.0 +

0.0*

Paw treading

0.0 ±

0.0

0.0 ±

0.0

Yawning*

0.1 ±

0.1

0.0 ±

0.0

Raring*

4.1 ±

1.8

4.3 ±

1.7

Immobility

396.1 ± 34.4 392.5 ± 38.0

89.0 ± 50.2* 140.3 ± 75.8*
0.0 ±
7.2 +

0.0
2.9

84.1 ± 56.3*

0.0 ±

0.0

13.3 ±

5.5

0.0 ±

0.0*+

Behavioral activity was determined in rats that were treated during
postnatal development with a DA D, agonist, SKF 38393 HCl (3.0 mg/kg
per day x 28 days, i.p., from day of birth) and/or the
catecholamine neurotoxin 6-OHDA HBr (200 nq i.c.v., salt form, at
3 days from birth; desipramine pretreatment, 1 hr). Rats were
challenged with SKF 38393 HCl (3.0 mg/kg i.p.) at 8 weeks from
birth and were immediately observed for stereotyped behaviors for
10 min.
Behaviors were thus quantified as described in Table 1
legend. Each group is the mean of 10 rats.
*p < 0.000 vs. saline control group; +p < 0.01 vs. 6-OHDA group.
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TABLE 3
Effect of neonatal 6-OHDA and ontogenetic SKF 38393 treatments on
concentrations of DA, 5-HT and their metabolites in the striatum
of adult rats.
MONOAMINES (nmol/g)
GROUP

n

Saline

6

SKF 38393

5

6-OHDA
SKF 38393
+
6-OHDA

10
9

DA

HVA

DOPAC

5-HT

5-HIAA

79.2±2.3

8.6±0,5

16.110.4

4.010.1

5.210.2

74.1±3.0

8.210.3

13.810.6

3.910.2

5.210.3

0.6+0.07* 0.110.03*

0 .110.02* 6.810.2* 7.010.3*

0.6±0.08*

0.210.08*

0.210.05*

6.210.2* 6,810.2*

Rats were treated daily with vehicle or SKF 38393 HCl (3.0 mg/kg
i.p.) for 28 consecutive days from birth in combination with
i.c.v. injection of 6-OHDA (200 jxg, salt form, 3 days after
birth; desipramine pretreatment, l hr) or its vehicle. Striata
were removed for assay at 11 weeks. Values are mean nanomoles
per gram of tissue ± S.E.M.
*p < 0.001 when compared to control group.
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TABLE 4
Computer-modeled parameters for dopamine inhibition of [3H)SCH 23390
binding in the striatal homogenates of saline, 6-OHDA, SKF 38393
and 'SKF 38393 + 6-OHDA' treatment groups of rats.

Group

% RH

K h (nM)

Kl (/iM)

Saline

75.1 ± 2.6

212.2 ± 26.8

30.9 ± 9.9

SKF38393

75.3 ± 3.2

231.6 ± 26.6

29.2 ± 6.8

6-OHDA

68.7 ± 2.6

272.5 ± 38.5

24.4 ± 4.0

SKF38393
+
6-OHDA

73.2 ± 2.0

275.0 ±59.2

30.5 ± 6.8

Rats were treated daily with vehicle or SKF 38393 HCl (3.0 mg/kg
i.p.) for 28 consecutive days from birth in combination with i.c.v.
injection of 6-OHDA HBr (200 /ig, salt form, 3 days after birth;
desipramine pretreatment, 1 hr) or its vehicle.
Striata were
removed for assay at 11 weeks. Competition curves were constructed
by using 14 concentrations of inhibitor, DA, to compete for 0.45 nM
[ HJSCH 23390 binding in rat striatum and were fit best by a twosite computer derived model where the affinity of [3H]SCH 23390 was
constrained to be equal (Kd » 0.61 nM) at both high (RH) and low
(RL) affinity sites. The dissociation constants for high (KH) and
low (Kt) affinity agonist-binding sites were thus determined by
using computer program (GraphPad Software Inc., San Diego, CA).
Data are expressed as mean values or percent ± S.E.M. of
8 determinations in each treatment group.
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TABLE 5
Effect of neonatal 6-OHDA treatment on concentrations of DA, 5-HT
and their metabolites In the striatum of rats

Honoamine
or Metabolite

Treatment
Saline (n=6)

% of Control

6-OHDA (n=9)

DA

67.83 ± 1.80

0.95 ± 0.16*

1.4

HVA

7.50 ± 0.53

0.14 ± 0.04*

1.9

DOPAC

14.45 ± 0.87

0.27 ± 0.05*

1.9

5-HT

3.52 ± 0.15

6.23 ± 0.55*

5-HIAA

6.53 ± 0.30

7.50 ± 0.60

177
115

Rats were treated at 3 days after birth with 6-OHDA HBr (200 pg,
l.c.v. salt form; deslpramine pretreatment, 1 hr) or Its vehicle.
Striata were removed for assay at 9 months.
Values are mean
nanomoles per gram of tissue 1 S.E.M. Numbers In parentheses are
numbers of samples per group.
*p < 0.001 when compared to vehicle control group.
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EFFECT OF SKF-38393 ON LOCOMOTOR ACTIVITY IN RATS
1000

800

First Injection

C_
CD
-M
CD

600

0)

S

ro

400

in

200
0

Acute Saline
Treatment

Acute SKF 38393
Treatment

Figure 1. Effect of first acute weekly SKF 38393 HC1 (3.0
mg/kg i.p.) injection on locomotor activity in rats. Rats
were treated during postnatal ontogeny with either saline
O f SKF 38393 Hcl (3,0 mg/kg i.p, daily x 28 days;0H|),
6-OHDA HBr (200 jig i.c.v., 3 days after birth; desipramine
pretreatment, 1 hr;H) or combined SKF 38393 + 6-OHDA
treatments (|). Rats were challenged at 6 weeks from birth
with SKF 38393 HCl (3,0 mg/kg i.p.), 10 min before
observation, and then were videotaped for their locomotor
response for 60 min. Locomotor activity represents the
distance (meters) traveled by each rat. Each bar indicates
the mean of 7 to 10 rats. * p < 0.05, vs. control group
challenged with SKF 38393 HC1; + p < 0.05, vs. same group
challenged with saline.

64

EFFECT OF SKF-38393 ON LOCOMOTOR ACTIVITY IN RATS
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Figure 2. Effect of second acute weekly SKF 38393 HCl (3.0
mg/kg i.p.) injection on locomotor activity in rats. Rats
were treated during postnatal ontogeny with either saline
(□)/ SKF 38393 HC1 (3.0 mg/kg i.p.) daily x 28 days; QQ),
6-OHDA HBr (200 pg i.c.v., 3 days after birth; desipramine
pretreatment 1 hr;g) or combined SKF 38393 + 6-OHDA
treatments (»• Rats were challenged at 7 weeks from birth
with SKF 38393 HCl (3.0 mg/kg i.p.), 10 min before
observation, and then were videotaped for their locomotor
response for 60 min. Locomotor activity represents the
distance (meters) traveled by each rat. Each bar indicates
the mean of 7 to 10 rats. * p < 0.05, vs. control group
challenged with SKF 38393 HC1; + P < 0.05, vs. same group
challenged with saline.

65

EFFECT OF SKF-38393 ON LOCOMOTOR ACTIVITY IN RATS
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Figure 3. Effect of fourth acute weekly SKF 38393 HC1 (3.0
mg/kg i.p.) injection on locomotor activity in rats. Rats
were treated during postnatal ontogeny with either saline
O , SKF 38393 HC1 (3.0 mg/kg i.p. daily x 28 days; Dffl) ,
6-OHDA HBr (200 jig i.c.v., 3 days after birth; desipramine
pretreatment, 1 hr; H) or combined SKF 38393 + 6-OHDA
treatments (■). Rats were challenged at 9 weeks from birth
with SKF 38393 Hcl (3.0 mg/kg i.p.), 10 min before
observation, and then were videotaped for their locomotor
response for 60 min. Locomotor activity represents the
distance (meters) traveled by each rat. Each bar indicates
the mean of 7 to 10 rats. * p < 0.05, vs. control group
challenged with SKF 38393 HC1; + p < 0.05, vs. same group
challenged with saline.
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DOPAMINE INHIBITION OF [3H]SCH 23390 BINDING
IN RAT STRIATUM
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Figure 4. Competition of DA for 0.45 nM [3H]SCH 23390
binding in the striatum of the saline group of rats. Rats
were treated with vehicle i.c.v. injection (bilateral;
desipramine pretreatment; 3 days after birth) and the
striata were removed 11 weeks from birth. The competition
curve in striatal homogenates was fit best by a two-site
computer derived model where the affinity of (JH]SCH 23390
was constrained to be 0.61 nM. Each data point represents
the mean of 8 determinations + S.E.M.. The competition curve
was analyzed as in table 4.
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DOPAMINE INHIBITION OF [3 H]SCH 23390 BINDING
IN RAT STRIATUM
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Figure 5. Competition of DA for 0.45 nM [JH]SCH 23390
binding in the striatum of the ontogenetic SKF 38393 group
of rats. Rats were treated ontogenetically with SKF 38393
HC1 (3.0 mg/kg i.p. daily x 28), the striata were removed at
11 weeks from birth. The competition curve was constructed
as in figure 4.

DOPAMINE INHIBITION OF [3H]SCH 23390 BINDING
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Figure 6. Competition of DA for 0.45 nM (3H]SCH 23390
binding in the striatum of the neonatal 6-OHDA group of
rats. Rats were treated neonatally with 6-OHDA HBr (200 jig
i.c.v., 3 days after birth; desipramine pretreatment), and
the striata were removed at 11 weeks from birth. The
competition curve was constructed as in figure 4.
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DOPAMINE INHIBITION OF [3H]SCH 23390 BINDING
IN RAT STRIATUM
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Figure 7. Competition of DA for 0.45 nM [JH)SCH 23390
binding in the striatum of the neonatal 6-OHDA plus
ontogenetic SKF 38393 group of rats. Rats were treated
ontogenetically with SKF 38393 HC1(3.0 mg/kg i.p. daily x
28) and lesioned neonatally with 6-OHDA HBr (200 /ig i.c.v.,
3 days after birth; desipramine pretreatment). The striata
were removed at 11 weeks from birth. The competition curve
was constructed as in figure 4.
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STRIATAL DOPAMINE D1 RECEPTOR mRNA LEVELS
BEFORE TREATMENTS WITH SKF 38393 IN ADULT RATS
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Figure 8A. Effects of neonatal 6-OHDA and ontogenetic SKF
38393 treatments on striatal mRNA levels for DA D, receptors
before treatments with SKF 38393 in adulthood. Each bar
represents the mean (± s.E.M.) ratio of optical density for
D, receptor mRNA vs. that for ft-actin mRNA. * p < 0.05 vs.
saline group.
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STRIATAL DOPAMINE Dl RECEPTOR mRNA LEVELS
AFTER TREATMENTS WITH SKF 38393 IN ADULT RATS
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Figure 8B. Effects of neonatal 6-OHDA and ontogenetic SKF
38393 treatments on striatal mRNA levels for DA D, receptors
after treatments with SKF 38393 in adulthood. Each bar
represents the mean (± S.E.M.) ratio of optical density for
D, receptor mRNA vs. that for fl-actin mRNA. No significant
differences were observed among saline, SKF 38393, 6-OHDA
and 'SKF 38393 + 6-OHDA' treatment groups.
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DOPAMINE-STIMULATED STRIATAL ADENYLATE CYCLASE
ACTIVITY IN RATS
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Figure 9. Effects of neonatal 6-OHDA and ontogenetic
SKF 38393 treatments on DA-stimulated adenylate cyclase
activity. Each point represents the mean (± S.E.M.) cAMP
production (pmoles/mg protein/min) of 5 to 6 determinations.
The basal enzyme activities for saline, SKF 38393, 6-OHDA
and SKF 38393 + 6-OHDA treatment groups are: 19.0 ± 2.7,
19.1 ±3.6, 14.7+2.3, and 19.6 ± 2.1 pmoles/mg
protein/min, respectively. No significant differences in
stimulation were observed between the treatment groups.
* p < 0.05, vs. basal activity in the same group.
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STRIATAL BASAL, NaF- OR FORSKOLIN-STIMULATED
ADENYLATE CYCLASE ACTIVITY IN ADULT RATS
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Figure 10. Effects of neonatal 6-OHDA and ontogenetic
SKF 38393 treatments on basal adenylate cyclase activity and
NaF- and forskolin-stimulated adenylate cyclase activity.
No significant differences were observed among saline,
SKF 38393, 6-OHDA and 'SKF 38393 + 6-OHDA' treatment groups
on basal enzyme activity. NaF and forskolin increased
adenylate cyslase activity in all treatment groups, but the
relative increase was not statistically significant among
these four groups of rats.
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SKF 38393-INDUCED ORAL ACTIVITY IN RATS
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Figure IX. Dose-response relationship for SKF 38393-induced
oral activity in rats. Numbers of oral movements were
determined for one minute every 10 minutes over a 60-min
period, starting 10 minutes after SKF 38393 HC1 (0.03 to
3.0 mg/kg i.p.). Each group is the mean of 4 to 6 rats.
The number of oral movements in 6-OHDA vs. control rats is
different at each respective dose of SKF 38393 (p < 0.01).
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ATTENUATION OF SKF 38393-INDUCED ORAL ACTIVITY
IN RATS BY SCH 23390
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Figure 12. Attenuation of SKF 38393-induced oral activity in
rats by SCH 23390. Numbers of oral movements were
determined for one minute every 10 minutes, for 60 minutes,
starting 10 minutes after SKF 38393 HC1 (0.3 mg/kg i.p.) and
60 minutes after SCH 23 390 HCl (0.3 mg/kg i.p.). Each group
is the mean of 4 to 6 rats. * p < 0.005 vs. other 6-OHDA
groups.
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m-CPP-INDUCED ORAL ACTIVITY IN RATS
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Figure 13. Dose-response relationship for m-CPP-induced oral
activity in control and 6-OHDA-lesioned rats. Rats were
studied for oral activity as in figure 11. Each bar
represents mean number of oral movements ± S.E.M.. Each
m-CPP dose produced a greater response in the 6-OHDA vs.
control group. * p < 0.01; ** p < o.ooi vs. respective
control or 6-OHDA group challenged with saline.
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EFFECTS OF SEROTONIN IA AND IB RECEPTOR AGONISTS
ON ORAL ACTIVITY IN RATS
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Figure 14. Effects of 8-OH-DPAT, a 5-HT,A receptor agonist,
and CGS-12066B, a 5-HTin receptor agonist, on oral activity
in control and 6-OHDA-lesioned rats. Rats were observed for
oral activity, as described in figure 11. The number of
oral movements was determined in the l-hr interval, starting
10 min after challenge treatment with saline, or 8-OH-DPAT
(0.1 mg/kg s.c.}, or CGS-12066B (3.0 mg/kg i.p.). Each
group is the mean of 8 to 9 (control) or 11 to 14 (6-OHDA
lesioned) rats. There was no statistically significant
increase in oral activity after 8-OH-DPAT or CGS-12066B
treatments.
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EFFECTS OF SEROTONIN RECEPTOR ANTAGONISTS
ON m-CPP-INDUCED ORAL ACTIVITY IN RATS
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Figure 15. Effects of 5-HT receptor antagonists on m-CPPinduced oral activity in control and 6-OHDA-lesioned rats.
Rats were studied for oral activity as in figure 11.
Mianserin HC1 (1.0 mg/kg s.c.), ketanserin tartrate
(5.0 mg/kg i.p.) and MDL 72222 (10.0 mg/kg i.p.) were
administered 30 min before m-CPP 2HC1 (1.0 mg/kg i.p.) or
its vehicle. Each group is the mean (± S.E.M.) of 6 to 11
rats. * p < 0.001 vs. m-CPP effect in the 6-OHDA-lesioned
rats.
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LACK OF EFFECT OF SCH 23390
ON m-CPP-INDUCED ORAL ACTIVITY IN RATS
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Figure 16. Lack of effect of SCH 23390 on m-CPP-induced oral
activity in control and 6-OHDA-lesioned rats. Rats were
studied for oral activity as in figure 11. SCH 23390
(0.3 mg/kg i.p.) was administered 1 hr before m-CPP 2HC1
(1.0 mg/kg i.p.) or its vehicle. Each group is the mean
(± S.E.M.) of 4 to 11 rats. SCH 23390 did not attenuate the
effect of m-CPP (p > 0.05).
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ATTENUATION OF SKF 38393-INDUCED ORAL ACTIVITY
IN RATS BY MIANSERIN
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Figure 17. Attenuation of SKF 38393-induced oral activity in
control and 6-OHDA-lesioned rats by mianserin. Rats were
studied for oral activity as figure 11. Mianserin HC1 (1.0
mg/kg s.c.) was administered 30 min before SKF 38393 HC1
(1.0 mg/kg i.p.) or its vehicle. Each group is the mean
(± S.E.M.) of 4 to 11 rats. * p < o.ooi vs. other groups.
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STRIATAL SEROTONIN 1C RECEPTOR mRNA LEVELS
BEFORE TREATMENTS WITH SKF 38393 IN AOULT RATS
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Figure 18A. Effects of neonatal 6-OHDA and ontogenetic
SKF 38393 treatments on striatal mRNA levels for 5-HTlc
receptors before treatments with SKF 38393 in adulthood.
Each bar represents the mean (± S.E.M.) ratio of optical
density for 5-HTir receptor mRNA vs. that for 0-actin mRNA.
No significant differences were observed among saline,
SKF 38393, 6-OHDA and 'SKF 38393 + 6-OHDA' treatment groups.
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STRIATAL SEROTONIN IC RECEPTOR mRNA LEVELS
AFTER TREATMENTS WITH SKF 38393 IN ADULT RATS
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Figure 18B. Effects of neonatal 6-OHDA and ontogenetic
SKF 38393 treatments on striatal mRNA levels for 5-HTIC
receptors after treatments with SKF 38393 in adulthood.
Each bar represents the mean (± S.E.M.) ratio of optical
density for 5-HTlt: receptor mRNA vs. that for B-actin mRNA.
No significant differences were observed among saline,
SKF 38393, 6-OHDA and 'SKF 38393 + 6-OHDA' treatment groups.

Chapter 4
Discussion

DR D. Receptor supersensitization
Neonatal treatment of rats with a catecholamine
neurotoxin, 6-OHDA, results in the supersentization of DA
receptors.

That is, doses of L-dihydroxyphenylalanine (L~

DOPA), apomorphine or SKF 38393 which have little effect in
intact rats, produce marked changes in stereotyped and
locomotor behaviors in the lesioned rats that were tested as
adults (Breese et al., 1984, 1985a,b, 1987; Hamdi and
Kostrzewa, 1991).

The DA Di receptor antagonist, SCH 23390,

attenuates the enhanced stereotyped and locomotor behaviors
by the D: agonist, SKF 38393, in the lesioned rats,
indicating that Dx receptors are specifically involved in
the induced receptor sensitization (Breese et al., 1985a,b,
1987).

The ability to sensitize D: receptors appears to be

related to immaturity of the DA system at the time of
lesioning, since 6-OHDA treatment of adult rats is not
associated with such receptor sensitization (Breese et al.,
1984).

Actually, a latent supersensitization of Dt

receptors occurs with this lesion, and the sensitization
process is only unmasked by repeated DA D: agonist
treatments in adulthood (Criswell et al., 1989, 1990;
Johnson et al., 1992).

This process of induction of long-

lived Dj receptor supersensitivity is known as 'priming'
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(Breese et al., 1985b; Criswell et al., 1989).

Recently,

Hamdi and Kostrzewa (1991) reported that the D, receptors
could be ontogenetically sensitized by repeated Dt agonist
treatments during the first 33 days after birth.

As in

adult-primed rats, there was an enhancement of the D,
agonist-induced stereotyped behaviors in adulthood.

Also,

as in studies by Breese and co-workers, there was no change
in the B,^ or Kj for D, binding in the striatum of these rats
(Breese et al., 1987).
The status of the DA Dt receptor during postnatal
ontogeny is not completely resolved.

There are some reports

of only slight change in the B ^ and Kd for []H]SCH 23390
binding to striatal homogenates in the first 1 to 2 months
after birth (Broaddus and Bennett, 1990), and other reports
of a dramatic increase in B„„ during the first 4 to 5 weeks
after birth (Giorgi et al., 1987; Zeng et al., 1988) and
even transient increases in the Kd in this interval (Zeng et
al., 1988).

Using histochemical methods, however, it has

been clearly demonstrated that DA D, receptors develop in
patches in the striatum, being closely associated with DA
nerve terminal input to these patches (Zeng et al., 1988).
As D, receptors increase in number, the striosomal pattern
of DA D, receptors becomes obscured by the global increase
in DA D| receptors in the matrix of the striatum.

This

pattern of DA D, receptor development indicates that the
early series of SKF 38393 treatments in the present study

would initially interact only with the population of DA D,
receptors that had developed up to that point in tine.
Interaction of SKF 38393 with striatal DA D, receptors would
change during development, as the population of the receptor
continued to increase in number during ontogeny.

In theory,

each subsequent dose of SKF 38393 was able to act at greater
numbers of Dt receptors, which would mean that there was
unequal exposure of the DA D, receptor population to the DA
D, agonist.

Perhaps this relates to the inability of SKF

38393 to fully sensitize DA D, receptors to later SKF 38393induced locomotor activity effects.
Although many SKF 38393-induced responses of neonatalsensitized and adult-primed rats are similar, there are some
differences in degree of response for many behaviors, which
possibly are related to the extent of sensitization.

The

extent of DA D, sensitization in those rats treated
repeatedly in postnatal ontogeny with the DA D, agonist, SKF
38393 was investigated in the present study.

For that

reason the locomotor responses to SKF 38393 were determined
after the first 2 doses and after the last dose of the D(
agonist.

It is clear from effects observed in rats treated

only with neonatal 6-OHDA, that adult priming was essential
for unmasking of the latent supersensitivity of D,
receptors.

In essence, the first dose of SKF 38393 produced

only a slight increase in the locomotor response of rats,
while subsequent doses produced increasingly greater effects
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(7th bars of figs. 1-3; p < 0.05, ANOVA).

This finding in

the present study is in full agreement with those earlier
reports (Breese et al., 1985b; Criswell et al., 1989, 1990).
In contrast to this effect, sensitization of DA Dt
receptors was evident with the first challenge dose of SKF
38393 at 6 weeks, in neonatal 6-OHDA lesioned rats that were
treated daily with SKF 38393 during the first 4 weeks of
postnatal ontogeny.

That is, an enhanced locomotor response

was observed after initial SKF 38393 treatment in adulthood
(8th bar of fig, l, p < 0.05).

Subsequent SKF 38393

challenge doses increased locomotor activity to a level
ultimately about 3-fold greater than that seen after the
first adult challenge dose (8th bars of figs. 2-3).
Therefore, it appears that ontogenetic treatments of
neonatal 6-OHDA-lesioned rats with SKF 38393 produces
partial but not complete DA D, receptor supersensitization.
Additional adult SKF 38393 treatments were necessary to
produce the maximal level of D, sensitivity.
Because locomotor activity is only one of several kinds
of behaviors induced by DA agonists, we observed rats for
SKF 38393-induced stereotypies at 8 weeks.

DA Dt agonists

produce exaggerated stereotyped behavioral responses in
neonatal 6-OHDA-lesioned rats (Breese et al., 1984, 1985a,b,
1987; Hamdi and Kostrzewa, 1991).

It was important to

determine if several SKF 38393 challenge treatments would
substantially modify the stereotypy effect of a DA Dt
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agonist in adult rats.

We found that ontogenetic SKF 38393

treatments did not markedly influence stereotyped responses
in neonatal 6-OHDA-lesioned rats.

Virtually all of the

behaviors were expressed in both the 6-OHDA group and 'SKF
38393 + 6-OHDA' group, except for taffy pulling, which was
expressed in only the latter group.

Also, immobility time

was less in this group vs. the 6-OHDA group.

These findings

suggest that ontogenetic SKF 38393 treatments are able to
partially modify later stereotyped behavioral effects of a
DA D| agonist.
Despite the fact that a different method was used in
the present study to evaluate stereotyped behavior,
virtually all of the SKF 38393-induced responses are similar
to those observed previously in rats that were lesioned
neonatally with 6-OHDA and ontogenetically sensitized with
SKF 38393 (Hamdi and Kostrzewa, 1991}.

The one exception is

that SKF 38393-induced grooming is reduced in the present
study, compared to an enhanced grooming response in the
previous study (Hamdi and Kostrzewa, 1991).

This difference

may relate to additional priming in adulthood in the present
study.

It is likely that, as D(-related behaviors became

more prominent with additional SKF 38393 treatments in
adulthood, the competing behaviors resulted in less grooming
behavior.

In essence, a rat can only exhibit so many

behaviors at one time, so an increase in performing of one
behavior might be expected to diminish the time spent in
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another behavior.
Given the behavioral aberrations observed in both
neonatal 6-OHDA-lesioned rats and those receiving combined
neonatal 6-OHDA and ontogenetic SKF 38393 treatments in the
present study, a DA competition for [3H]SCH 23390 binding
analysis was performed from striatal homogenates of the
rats.

This was done because earlier reports showed a lack

of change of D, receptor number and affinity by either using
striatal homogenates (Breese et al., 1987; Duncan et al.,
1987; Dewar et al., 1990; Hamdi and Kostrzewa, 1991) or
performing autoradiography (Luthman et al., 1990; Simson et
al., 1992), after neonatal 6-OHDA treatment.

As yet, very

little is known about whether numbers of high affinity D,
receptor would be altered in these rats or in rats given
both neonatal 6-OHDA and ontogenetic D, agonist treatments.
No change in high affinity binding sites for DA D, receptors
was noted in neonatal 6-OHDA vs. saline rats when using DA
competition for radiolabeled D, antagonist binding (table
4).

Also, in the present study postnatal treatment of

neonatal 6-OHDA-lesioned rats with SKF 38393 did not affect
the distribution of high and low affinity agonist binding
sites (table 4).

Collectively, these results demonstrate

that behavioral supersensitivity to systemic administration
of DA D| agonist in adulthood, or priming of rats lesioned
as neonates and those given neonatal lesion plus ontogenetic
treatment with the D, agonist, is neither due to increased D,
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receptor number in general, nor is it due to altered high
affinity receptor binding in particular.
With the techniques of recombinant DNA technology being
used, specific sequences encoding different types of DA
receptor including rat (Zhou et al., 1990) and human D,
receptors (Dearry et al., 1990; Sunahara et al., 1991), have
been cloned .and sequenced, and thereby can be used to
analyze the receptor gene expression in the brain.
Therefore, availability of the receptor mRNA probe has made
it possible to analyze the specific mRNA coding for DA D(
receptor and thus to have a better understanding of the
receptor regulation and supersensitivity after neonatal 6OHDA lesion.

In order to investigate whether the enhanced

locomotor and stereotyped responsiveness of the lesioned
rats to adult challenge doses of D, agonist is attributable
to an altered rate of transcription of the gene or the mRNA
for DA D, receptors, we also evaluated the effect of SKF
38393 treatments on expression of the gene coding D,
receptors.

The finding that the level of D, receptor mRNA

after neonatal 6-OHDA was reduced, regardless of whether
ontogenetic SKF 38393 was co-administered, suggests that 6OHDA chemical lesion influences the receptor gene
expression.

Gelbard et al. (1990) demonstrated that

neonatal development of DA D, receptors in rat forebrain was
impaired after 6-OHDA lesion.

These investigators suggested

that in the absence of endogenous DA, the Dt receptors may

possibly either fail to develop adequately or fail to be
maintained.

The present data reveal possible molecular

mechanisms underlying this biochemical event.

Our finding

indicates that neonatal 6-OHDA lesion impairs ontogeny of DA
Dj receptors due to failure of receptor gene expression.
After repeated treatments with SKF 38393 in adulthood (adult
priming), there was no change in striatal Dt mRNA levels
among the treatment groups, indicating that priming restores
D, receptor gene expression in the lesioned rats.

These

results are in accord with previous studies, demonstrating
that priming of striatal D, receptors in neonatal 6-OHDA
lesioned rats occurred in the absence of altered D, receptor
density and affinity (Breese et al., 1987; Duncan et al.,
1987; Dewar et al., 1990; Luthman et al., 1990; Hamdi and
Kostrzewa, 1991).

Moreover, these findings are fully

consistant with the above agonist competition for
radiolabeled DA D, antagonist binding data, indicating that
the DA D| receptor recognition site after neonatal 6-OHDA
lesion may not be a critical factor in the development of
behavioral supersensitivity to DA D, agonist.
Based on pharmacological manipulation of adult animals,
it has been proposed that alterations in DA D, receptor mRNA
by repeated reserpine treatments (Butkerait and Friedman,
1993) or by chronic DA D, receptor blockade (Schettini et
al., 1992) are associated with an increased level of mRNA
coding for G protein alpha subunit (Nsa). The present data

showed that after adult priming with a D, agonist, the level
of Dt receptor mRNA in neonatally lesioned or combined
neonatally lesioned plus ontogenetically sensitized rats did
not differ from that of the control at a time when
behavioral sensitization of the animals is known to occur.
Taken together, these studies suggest that a site distal to
the DA D| receptor recognition site, or possibly, a site
rather than in DA neurochemical system but in a system or
systems modulating DA-mediated effects, accounts for the
apparent supersensitization of D, receptor-related function.
The present study, using DA to stimulate adenylate
cyclase in the presence of spiperone, indicates that the
link of DA D, receptors to this enzyme is not changed in the
striatum by lesioning neonates with 6-OHDA, in spite of
profound depletion of striatal DA content and
supersensitized behavioral responses.

Moreover, we found

that forskolin- and NaF-stimulated adenylate cyclase
activity did not differ in lesioned and intact rats.
Additionally, ontogenetic treatments with SKF 38393 failed
to affect basal and DA-stimulated adenylate cyclase activity
in both neonatal lesioned and intact animals.

This finding

supports that of Sirason et al. (1992), who found that
agonist-stimulated adenylate cyclase activity did not change
in neonatal 6-OHDA lesioned rats that were primed in
adulthood.

It appears that DA Dt receptor linked adenylate

cyclase is also not a major determinant of supersensitized
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behavioral responses to D( agonists in neonatal 6-OHDAlesioned rats.
It is well established that neonatal 6-OHDA treatment
of rats is associated with a marked reduction in the
t

striatal level of DA, due to destruction of nigrostriatal
neurons (Breese and Traylor, 1971, 1972; Breese et al.,
1984), and an elevation in 5-HT content (Breese et al.,
1984; Stachowiak et al., 1984), due to sprouting and ensuing
hyperinnervation by 5-HT-containing fibers (Stachowiak et
al., 1984; Berger et al., 1985; Luthman et al., 1987; Towle
et al., 1989).

The findings in this study are in full

agreement with those earlier reports.

That is, DA content

of the striatum in 6-OHDA-lesioned rats is profoundly
reduced by nearly 99%, and DOPAC and HVA contents are
reduced by a similar amount (table 3).

Accompanying these

changes is the elevation of striatal 5-HT content by 70%,
and 5-HIAA by 35% (table 3).

Additionally, ontogenetic

treatments of rats with SKF 38393 in the present study, did
not produce an effect on striatal DA, 5-HT and their
metabolites, nor did this treatment modify the effect of 6OHDA (table 3).

Based on above striatal contents of DA, 5-

HT and their metabolites found in this study, we feel that
the animal models are similar to those in earlier studies.
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Mediation of DR Agonist-Induced oral Behavior bv the 5-HT
System
In neonatal 6-OHDA-lesioned rats a supersensitized
response to DA D, agonists is observed in adulthood (Breese
et al., 1985a,b, 1987; Hamdi and Kostrzewa, 1991), despite
the lack of change in number or affinity of D, receptors
(Breese et al., 1987; Hamdi and Kostrzewa, 1991).

The oral

activity response to D, receptor agonists and D2 antagonists
is also enhanced in the neonatal lesioned rats (Kostrzewa
and Hamdi, 1991).

In the present study, the augmented oral

response to SKF 38393 in lesioned rats is attenuated by SCH
23390, a DA D, receptor antagonist, indicating that the Dt
receptor subtype is primarily involved in the enhanced
response (fig. 12).
Recently, it was found that 5-HT agonists also can
induce oral activity in rats (Stewart et al., 1989).

Since

the striatal DA depletion in neonatal 6-OHDA-treated rats is
accompanied by elevated 5-HT levels (Breese et al., 1984;
Stachowick et al., 1984; Luthman et al., 1987; table 5 in
the present study) and hyperinnervation of striatum by 5-HT
fibers (Berger et al., 1985; Snyder et al., 1986), it was of
interest to determine whether the induction of oral activity
by 5-HT agonists would be potentiated in these rats.

The

enhanced response to m-CPP over a wide dose range in
lesioned rats in this study, demonstrates that 5-HT
receptors are also supersensitized in this group of rats.
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Production of overt supersensitization of 5-HT receptors in
neonatal 6-OHDA-lesioned rats is suggested by the fact that
the maximal oral activity response is 2- to 3-fold higher in
this group vs. control (fig. 13).

It has also been shown

that m-CPP acts directly as a 5-HT agonist that lacks 5-HT
uptake inhibitor properties (Fuller et al., 1981).
Therefore, the most likely explanation for m-CPP action
relates to 5-HT receptor supersensitization.
The series of studies with 5-HT receptor agonists and
antagonists indicate that 5-HTu and 5-HT,B receptors are not
associated with oral activity.

The agonist, 8-OH-DPAT, is

relatively selective for 5-HT,A receptors (Arvidsson et al.,
1981; Hiddlemiss and Fozard, 1983}, and the dose used in the
present study is known to produce a response in vivo (Fuller
and Snoddy, 1987; Stewart et al., 1989).

CGS 12066B, a

selective 5-HT,B receptor agonist with little activity at D,
sites (Neale et al., 1987), did not induce oral activity.
Although we have no direct evidence that CGS 12066B acted at
the 5-HT|B site in the brain, the dose used in this study is
more than 10-fold greater than that found by others to alter
the firing of dorsal raphe neurons (Neale et al., 1987).
Ketanserin and MDL 72222, antagonists with high
affinity for 5-HT2 (Leysen et al., 1981, 1982) and 5-HTj
(Fozard, 1984) receptors, respectively, were ineffective in
attenuating the enhanced oral response to m-CPP.

The doses

of ketanserin and MDL 72222 are similar or higher than that
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known to produce antagonism of 5-HT2 and 5-HTj receptors in
vivo (Fozard, 1984; Awouters et al., 1990; Nash, 1990).
These findings suggest that 5-HT2 and 5-HT3 receptors are not
involved in the effect of m-CPP.

Attenuation of the

enhanced oral response to m-CPP by mianserin, an antagonist
with affinity for both 5-HTlc and 5-HT2 receptors, suggests
that it is the 5-HTlc receptor subtype that becomes
supersensitized after loss of DA input to the striatum.
It was not practical to use a wide range of doses for
the different agonists and antagonists in these studies, and
it is conceivable that a different dose and/or different
observation time for some of these agents might have
resulted in an effect on the oral response.

However, based

on findings with 5-HT receptor agonists and antagonists in
this study, there is an apparent correlation between 5-HT,c
receptors and the oral responses of rats.
In the present study, the other major finding

is the

lack of effect of SCH 23390 on m-CPP-induced oral activity.
This indicates that the DA system is not the final pathway
in the behavioral event.

This finding is in agreement with

our biochemical studies in which there was no alteration in
DA D, receptor high affinity binding sites, no change in
basal and DA-stimulated adenylate cyclase activity, and no
change in Dt receptor mRNA level after priming in adulthood.
SCH 23390 has a high affinity for the D, receptor, with an
ICH

for [3H]SCH 23390 binding being about 150 times less

than that for [3H)mesulergine binding (Billard et al., 1984;
Hoyer et al., 1988).

The dose of SCH 23390 in this study is

similar or identical to that used to specifically attenuate
oral activity responses to a D, agonist (Levin et al., 1989;
Rosengarten et al., 1986); to attenuate Dj agonist-induced
behaviors (Breese et al., 1985a,b; Criswell et al., 1989);
and to attenuate the development of D, receptors (Saleh and
Kostrzewa, 1988; Kostrzewa and Saleh, 1989).
The effectiveness of mianserin in attenuating the
enhanced oral response to SKF 38393, suggests that D,
receptor-mediated oral activity relies on a 5-HT
neurochemical system for transduction of the response.

The

DA and 5-HT pathways associated with oral activity may
operate in sequence, with the 5-HT system representing a
later stage in this circuit.

It is also possible, however,

for these two neurochemical systems to operate in parallel
but with the 5-HT system exerting greater control.
Antagonists of the 5-HT system could conceivably attenuate
D, agonist-induced oral responses in either design.

The

observed oral response may be a consequence of 5-KT fiber
sprouting and hyperinnervation in rostral striatum.
Additional studies are needed to resolve these aspects of
interaction between the DA and 5-HT neurochemical systems.
In other studies on neonatal 6-OHDA-lesioned rats it was
reported that the sprouted 5-HT fibers did not seem to
possess an inhibitory control on endogenous 5-HT- and
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acetylcholine-containing neurons (Jackson et al., 1988), and
that 5-HT innervation did not appear to be responsible for
supersensitized locomotor and stereotyped responses to a DA
agonist (Towle et al., 1989).

The present findings

demonstrate that 5-HT neurons can be intricately involved in
mediation of supersensitized responses to DA agonists.
To study the effects of neonatal 6-OHDA lesion and
ontogenetic SKF 38393 treatments on gene expression for 5HTIC receptors, the mRNA levels for the receptor subtype
were also determined in the present study.

Unlike DA D,

receptors, neither neonatal 6-OHDA nor ontogenetic SKF 38393
treatments affect mRNA coding for the 5-HTlc receptor.
Also, repeated treatments of both intact and lesioned rats
with SKF 38393 in adulthood did not influence the levels of
mRNA for 5-HT,c receptors in the striatum.

Therefore, the

biochemical change responsible for the enhanced oral
response in 6-OHDA-lesioned rats, other than altered gene
expession for 5-HTlc receptors, is yet to be determined.

It

has been known that 5-HT,c receptors are coupled to the
breakdown of phosphatidylinositides (Conn and Sanders-Bush,
1986).

An increase in inositol trisphosphates (IP3) was

reported to be related to the supersensitization of 5-HTlc
receptors generated by chemical denervation (Conn et al.,
1987).

It may be that coupling of the receptor with this

second messenger system could be different in the
supersensitized 5-HT,c receptors in our neonatal 6-OHDA rat

model.

Alternatively, balance and adjustment among striatal

DA, 5-HT and other neuronal systems after neonatal 6-OHDA
lesion may be responsible for the supersensitization of
multiple neural receptor systems (Kostrzewa and Heely,
1993).
The present series of studies helps to identify the
altered 5-HT receptor responses that occur in those rats
with greatly increased oral activity after neonatal
destruction of DA-containing fibers in the brain.

This

animal model should be useful in studying functional
associations between central dopaminergic and serotonergic
neurons.

Also, the discovery of a 5-HT neurochemical

component in enhanced oral dyskinetic activity implicates
another direction that may be taken toward the discovery of
agents that modulate dyskinetic oral activity in assorted
human clinical disorders.

Chapter 5
Summary

The present series of studies has demonstrated the
following:
1. Ontogenetic treatments of neonatal 6-OHDA-lesioned rats
with a DA Dt agonist, SKF 38393, can partially sensitize Dj
receptors in adulthood.
2. Neonatal 6-OHDA chemical lesions impair DA Di receptor
ontogeny due to failure of gene expression for the receptor,
while repeated treatments of the lesioned rats with SKF
38393 in adulthood result in restoration of the mRNA level
for D! receptors.
3. Changes in DA Dj receptor high affinity binding, Dx
receptor mRNA levels, and

receptor-stimulated adenylate

cyclase activity, can not account for supersensitized
behavioral responses in neonatally lesioned rats.
4. The 5-HTlc receptor subtype becomes functionally
supersensitized after neonatal destruction of DA input to
the striatum, in the absence of a change in striatal mRNA
level for this receptor subtype.

Moreover, induction of

oral activity by a DA D! agonist is mediated via a
serotonergic system.
5. The neonatal 6-OHDA rat model should be useful in
exploring functional and neurochemical associations between
central dopaminergic and serotonergic systems.
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